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I  Localized scleroderma (morphea)  
 
Introduction  
Localized scleroderma (LS) comprises a spectrum of sclerotic diseases that primarily affect the 
skin. Depending on the respective subtype, LS can also involve adjacent tissues such as the fat, 
fascia, muscle and bone.1 Debate continues as to whether the term “localized scleroderma” or 
“morphea” should be used for the disease because “localized scleroderma” or “circumscribed 
scleroderma” might be confused with “systemic scleroderma”, resulting in unnecessary patient 
concern. However, this will change over time because consensus has been reached to abandon 
systemic scleroderma for the term “systemic sclerosis”.2 Nevertheless, especially in Europe, the 
term LS is used as a heading for the whole spectrum of subtypes, whereas morphea is mainly 
used for the plaque type of the disease. In contrast to systemic sclerosis, LS does not affect 
internal organs such as the lungs, heart, kidneys or gastrointestinal tract. Although LS and 
systemic sclerosis (SSc) share similar pathogenetic pathways, both diseases rarely coexist, and 
transition from LS to SSc does not occur.  
 
Epidemiology 
LS is a rare disease that seems to be most frequent in white individuals, but may affect people 
of all ethnic backgrounds.3–5 To date, only a few adequate epidemiologic studies on LS have 
been conducted, with incidence ranging from 0.4 to 2.7 per 100.000 people.6,7 LS occurs more 
often in women than men, at a ratio of 2.6–6 to 1.8 The disease may manifest at all ages, but the 
peak age of incidence differs depending on the LS subtype. The most frequent subtype of LS 
(morphea) usually appears in adults between 40 and 50 years of age, whereas linear subtypes 
primarily present in childhood between 2 and 14 years of age.3 Other, rarer subtypes of LS have 
a peak incidence in the third and fourth decade of life.  
 
Pathogenesis 
The hallmark feature of LS is overproduction of collagen and increased extracellular matrix 
deposition. Its exact initiation remains unknown. It has been hypothesized that certain stimuli, 
for example infections, trauma, radiation, or drugs, might cause microvascular injuries and 
induce T cell activation that subsequently result in a release of various adhesion molecules.3 
Up-regulation of some of these adhesion molecules (e.g. vascular cell adhesion molecule-1 and 
intercellular adhesion molecule-1) might induce T cell activation, which, in turn, activates the 
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release of key player pro-fibrotic cytokines, such as transforming growth factor-beta (TGFβ) 
and its signal transducers called SMAD proteins, platelet-derived growth factor, connective 
tissues growth factor, and interleukin 4, 6, and 8.9–12 This pro-fibrotic pathway additionally 
includes a spectrum of chemokines that significantly contribute to skin sclerosis.13,14 
Ultimately, and similarly to SSc, activation of all of these pro-inflammatory and pro-fibrotic 
signals leads to excessive collagen production and decrease of matrix metalloproteinases 
(MMP) responsible for collagen degradation.15 
 
Potential trigger factors of localized scleroderma 
Although much is known about the early inflammatory phase and the molecular mechanisms 
involved in the fibroblastic reaction of LS, little is known about the potential triggers of the 
disease. Among infectious agents, Borrelia organisms have been extensively studied on both 
sides of the Atlantic. Whereas high rates of Borrelia infections, some of which were detected 
using highly sensitive new detection techniques such as focus-floating microscopy, have been 
reported in LS patients from Europe, a variety of studies based on polymerase chain reaction 
(PCR) from northern Europe or from the United States failed to demonstrate an association.16–
18 Thus, the pathogenetic role of Borrelia in LS remains unclear. Among the drugs that have 
been reported to induce LS, most evidence exists for bleomycin, D-penicillamine, vitamin K1, 
and L-5-hydroxytryptophane plus carbidopa. Recently, balicatib, an inhibitor of the osteoclastic 
enzyme cathepsin K used for osteoporosis, has been reported to induce LS.19 Few reports exist 
on radiation-induced LS, which primarily occurs in women with breast cancer.20,21 Clinically, 
radiation-induced LS might be indistinguishable from chronic radiodermatitis, but 
histopathologic analysis usually discerns both conditions. Finally, among the triggers of LS, 
mechanical injuries and traumata have been reported in case series and large cohort studies, 
with the highest association in facial subtypes of childhood LS.4,5,22 
 
Clinical manifestation 
Clinical classification 
To date, no uniformly accepted classification for LS exists. A widely accepted classification 
was published in 1995 that distinguishes plaque, generalized, deep, bullous, and linear types as 
the five main groups of LS.23 However, this classification raises some concerns. First, it 
includes diseases that are not uniformly accepted to belong to the LS spectrum, such as 
extragenital lichen sclerosus. Secondly, bullous lesions can appear in all different LS subtypes 
due to the characeristic subepidermal edema and damage of the basement membrane zone. 
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Thirdly, there are patients, especially children, who present with more than one subtype of LS. 
Thus, an alternative classification scheme was published in 2006 to overcome these 
weaknesses.24 A German group of experts proposed a classification (Table 1) that considers the 
extent and depth of fibrosis, and refers to the treatment of the respective subtypes.1 
 
<TABLE 1> 
 
Limited types of LS 
Plaque-morphea (the classical plaque type of LS) is the most frequent subtype of LS, especially 
in adults. In the early active phase, plaque-morphea usually presents with oval-shaped lesions 
surrounded by an erythematous border (the so-called “lilac ring”). In the later stage of disease, 
morphea lesions become hard and sclerotic in the center, with a whitish or ivory color. Older 
lesions may also become atrophic, hypo-, or hyperpigmented and, depending on the location of 
fibrosis, may also lead to hair loss and loss of the skin appendages. Plaque-morphea is 
frequently located on the trunk, especially the submammary region, the transitional area 
between the hip and inguinal regions or in areas with repeated trauma such as pressure from 
clothing. 
 
Guttate morphea is a rare subtype of morphea that presents with multiple yellowish or whitish, 
small sclerotic lesions with a shiny surface. Guttate morphea is predominantly located on the 
trunk. Early inflammatory lesions may simply present as erythematous maculae. Clinically and 
histopathologically, guttate morphea might be difficult to distinguish from extragenital lichen 
sclerosus. 
 
Atrophoderma of Pasini and Pierini is possibly an early abortive type of morphea. The recently 
described term “superficial morphea” seems to be synonymous with atrophoderma of Pasini 
and Pierini.25,26 The clinical presentation of this subtype of LS, which frequently manifests in 
childhood, is characterized by symmetrical, single or multiple, sharply demarcated, 
hyperpigmented, non-indurated patches that are located on the trunk or extremities. 
 
Generalized types of LS 
Generalized localized scleroderma is a more severe variant of LS. According to Laxer and 
Zulian, generalized localized scleroderma is defined as the presence of four or more indurated 
plaques of more than 3 cm in diameter, involving at least two of the seven anatomic sites (head-
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neck, each extremity, anterior trunk, and posterior trunk).24 The trunk is commonly affected 
and skin lesions are often distributed symmetrically and tend to coalesce. 
 
A unique and very rare variant of the generalized type of LS is “disabling pansclerotic 
morphea.” Disabling pansclerotic morphea, predominantly occurring in childhood, and may 
lead to extensive involvement of the skin, fat tissue, fascia, muscle, and bone, with only limited 
tendency of fibrosis to regress. Disabling pansclerotic morphea often results in severe 
contractures and poorly healing, large ulcerations and skin necroses. 
 
Linear types of LS 
Linear localized scleroderma is the most common subtype of LS in childhood. Linear LS is 
characterized by longitudinally arranged linear, band-like lesions that are predominantly 
located on the extremities. Evidence indicates that linear LS may follow the lines of Blaschko.27 
In mild disease, the lesions may heal with residual hyperpigmentation. However, depending on 
the extent of the fibrotic process, linear LS may lead to severe growth retardation, muscle 
atrophy, flexion contractures, myositis and myalgia, arthritis and arthalgia, and psychologic 
disability. 
 
LS “en coup de sabre” is a subtype located on the frontoparietal region of the head, usually 
ranging paramedian from the eyebrows into the hair-bearing scalp where it might cause scarring 
alopecia. Involvement of the underlying central nervous system (CNS; e.g. seizures, migraine, 
and headache) and abnormal ophthalmologic findings (e.g. uveitis) can occur. 
 
Several authors have speculated that progressive facial hemiatrophy (also called Parry–
Romberg syndrome) and LS “en coup de sabre” are variants of the same condition.1,5,28,29 
Progressive facial hemiatrophy is clinically characterized by a primary atrophy of the 
subcutaneous tissue, muscle, and bone. Skin fibrosis is usually absent. It often occurs in 
childhood or adolescence, and may result in severe facial asymmetry. Occurrence of 
simultaneous linear LS “en coup de sabre” and progressive facial hemiatrophy is quite frequent, 
with a reported coincidence of up to 40%.30 In the classification proposed in this article, 
progressive facial hemiatrophy is listed under the linear subtypes of LS (Table 1), although with 
exclusive involvement of extracutaneous structures it may also be classified as a “deep subtype” 
of LS. 
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Deep type of LS 
The deep type of LS (also called deep morphea) is the rarest variant, affecting less than 5% of 
patients. In deep morphea, the fibrotic process mainly affects the deeper layers of the connective 
tissue (i.e. fat tissue, fascia, and underlying muscle). Deep morphea lesions are typically 
arranged symmetrically and predominantly located on the extremities.  
 
Mixed type of LS 
Mixed types of LS predominantly affect children, occurring in up to 15% of patients with 
juvenile LS. Mixed types often consist of linear LS and morphea (plaques type of LS) or a 
combination of linear and generalized LS.5 
 
Eosinophilic fasciitis 
Eosinophilic fasciitis (or Shulman syndrome) is considered by many experts to be a special 
subtype belonging to the spectrum of LS.1. A mechanical trauma often precedes the first 
manifestation of the disease. Clinically, eosinophilic fasciitis predominantly affects the 
extremities and presents with a rapid onset of symmetrical swelling of the skin. In the later stage 
of disease, lesions become more indurated and fibrotic, leading to the typical “peau d’orange” 
like appearance. A distinctive clinical finding in later stages of eosinophilic fasciitis is that 
cutaneous veins might appear depressed compared with the surrounding tissue (called “negative 
vein sign”).  
 
Association with other autoimmune diseases 
Several reports of familiar clustering and increased rates of other autoimmune diseases (e.g. 
Hashimoto thyreoiditis, alopecia areata, vitiligo, and type-1 diabetes) in patients with LS 
suggest a possible genetic component.5 However, in contrast to SSc, susceptibility genes for LS 
are still unknown. In a study including 245 patients with LS, 17.6% had other rheumatic or 
autoimmune diseases. This rate is four times higher than in the general population. Patients with 
generalized LS had the highest rate of associated autoimmune diseases (45.9%).31 Another 
study that retrospectively evaluated 472 patients with LS for other autoimmune diseases found 
other autoimmune diseases in 8.1%.32  
 
Some decades ago, the coexistence of LS and lichen sclerosus (predominantly extragenital) was 
reported in several case reports and small case series.33,34 In 2012, a prospective study from 
France including 76 patients with LS showed that 38% of them had concomitant genital lichen 
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sclerosus; mostly patients with limited LS (morphea) and generalized LS were affected. This 
high rate of genital lichen sclerosus in patients with LS was later confirmed by a larger 
retrospective German study.35  
 
Clinical course, disease activity, and recurrence rates 
To date, only limited data are available on the long-term clinical course of LS. A recent 
retrospective analysis including 344 patients with adult or juvenile LS from the Netherlands 
demonstrated that about one quarter of the patients experienced a reactivation of disease. 
Univariate analysis demonstrated that the age at onset of disease was a risk factor for recurrent 
disease; relapses occurred significantly more often in pediatric LS (27%) compared with adult 
disease (17%). Moreover, disease subtype was another risk factor; 37% of patients with linear 
LS of the limbs (either solitary or as part of mixed type of LS) experienced a relapse, whereas 
recurrences in the other subtypes occurred less frequently (17%). The two most frequent 
subtypes in adults (morphea/plaque type and generalized LS) had recurrence rates of 16% and 
25%, respectively. Importantly, this study also showed that disease relapses can occur after 
years of quiescent disease; the median time between disease remission and first recurrence was 
26 months in juvenile and 27 months in adult LS, respectively.36 In the study of Saxton-Daniels 
et al. regarding long-term outcome of pediatric cases, 89% of the pediatric onset cases 
developed new or expanded lesion over time.37 Time to recurrence of activity ranged from 6 to 
18 years from initial disease onset. 
 
Diagnostic procedures 
Laboratory parameters   
Depending on the clinical subtype, a high incidence of autoimmune phenomena has been 
reported in LS patients (e.g. serum antinuclear antibodies, most of them with a homogenous 
pattern).4,31,38 Moreover, active childhood LS might be associated with anti-histone antibodies, 
hypergammaglobulinemia, and eosinophilia.39 In patients with linear LS of the extremities with 
concomitant joint involvement, increased levels of rheumatoid factor may be present, and do 
sometimes correlate with the clinical degree of arthritis activity.40 Several other antibodies (e.g. 
anti-topoisomerase II alpha, anti-U1-small-nuclear-ribonucleoprotein, and anti-U3-small-
nuclear-ribonucleo-protein), and anti-MMP antibodies have been evaluated in LS, but their 
specific role remains to be elucidated.41–43 
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In daily practice, blood screening in patients with LS who are considered for systemic therapy 
should include blood differential and serum chemistry (Table 2). Routine screening for 
antinuclear antibodies is not recommended. Additional diagnostics (e.g. screening for 
antibodies against extractable nuclear antigens) should be only performed to confirm or exclude 
systemic sclerosis.  
 
Controversy exists about the pathogenetic role of Borrelia burgdorferi in LS (see Potential 
trigger factors of LS, above). Accordingly, a general blood screening for Borrelia in patients 
with LS is not generally recommended and should only be performed in clinically suspicious 
cases. 
 
<TABLE 2> 
 
Histopathology of localized scleroderma 
LS and SSc share the same histopathologic features. Thus, by histopathology, it is neither 
possible to distinguish between LS and SSc nor to differentiate among different LS subtypes. 
In general, two phases of LS can be recognized, an early inflammatory and a late fibrotic 
stage.1,44 Early skin lesions of LS are characterized by thickened collagen bundles within the 
reticular dermis that run parallel to the skin surface, and by the presence of dense inflammatory 
infiltrates between the collagen bundles, and around blood vessels and sweat glands. 
Lymphocytes predominate the inflammatory infiltrates, but plasma cells, histiocytes, and 
eosinophilic granulocytes might be present as well. The overlying epidermis might be either 
unaffected or thin and atrophic. In the late fibrotic stage, the lesional skin becomes relatively 
avascular, and often there is only little evidence of ongoing inflammation. Late lesions usually 
contain collagen fibers that are tightly packed and highly eosinophilic. Sweat glands are 
atrophic or absent. Collagen may replace fat cells in the subcutaneous tissue. Physicians should 
ensure that the biopsy excision is sufficiently deep as some LS subtypes may primarily involve 
the subcutis or underlying fascia and muscle. 
 
Clinical scores 
Due to the difficulties of defining clinical improvement in LS, clinical scores were not available 
for a long period of time. The Rodnan Skin Score (RSS) and its later revised version (the so-
called “modified RSS) are validated and widely used clinical tools in SSc.45 Both of these scores 
are inappropriate for the measurement of LS skin involvement due to the overweight of certain 
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anatomic areas (e.g. face), which are usually spared in LS. In 2009, the first validated skin score 
for LS, called the modified Localized Scleroderma Skin Severity Index (mLoSSI) was 
introduced. This score evaluates erythema, skin thickness and development of new skin lesions 
or lesional extension in 18 anatomic regions, and has demonstrated a high interrater 
agreement.46 The same group of researchers later introduced a score for skin damage in LS, 
called the Localized Scleroderma Skin Damage Index (LoSDI).47 Consequently, it was 
recommended to combine the mLoSSI, LoSDI, and the Physician’s Global Assessment (PGA) 
to measure both activity and damage in LS. This composes the Localized Scleroderma 
Cutaneous Assessment Tool (LoSCAT), a combined score that is modeled after a well 
established tool for cutaneous lupus erythematosus, the Cutaneous Lupus Erythematosus 
Activity and Severity Index (CLASI). LoSCAT, which is similar to the CLASI, could become 
a standard tool to evaluate skin affection in LS. 
 
Patient quality of life can be evaluated with the Dermatology Life Quality Index (DLQI) or the 
Hospital Anxiety and Depression Scale. 
 
Radiologic examination 
Morphea, the most common LS subtype in adults, usually affects the skin only and therefore 
does not require further radiologic examination. In contrast, patients with LS “en coup de sabre” 
and progressive facial hemiatrophy often suffer from neurologic symptoms (e.g. migraine, 
headache, and epilepsy). In these cases, cranial magnetic resonance imaging (MRI) should be 
considered to detect potential involvement of the CNS because subcortical calcifications and 
brain atrophy are common.4,22 In special cases ophthalmologists or oral surgeons should be 
consulted about abnormalities that have to be corrected. Despite such abnormalities of the CNS, 
many patients are asymptomatic. In addition, MRI and computed tomography studies might be 
helpful for surgical planning (e.g. in LS “en coup de sabre” type), and to detect muscle, joint or 
bone involvement, for instance in linear LS of the extremities. MRI should be considered in 
cases with linear LS of the extremities that might have concomitant arthritis. 
 
Technical outcome measures 
A variety of technical procedures have been reported in clinical trials on LS, for example, 
ultrasound scanning, cutometer, durometer, thermography, laser Doppler flowmetry, and a 
computerized skin score. In most of the studies, these procedures were used as secondary 
outcome measures.  
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Differential diagnoses 
A variety of differential diagnoses should be considered in LS.48 In daily routine, the physicians’ 
pivotal challenge is to differentiate LS from SSc.3 Typical facial (e.g. telangiectasia, beak-
shaped nose, and microstomia) and vascular (e.g. Raynaud’s phenomenon, pitting scars, and 
digital ulcers) features of SSc, as well as highly specific serum antibodies (e.g. anti-centromere 
antibodies and anti-Scl-70 antibodies) are absent in LS.44 
 
The most relevant differential diagnoses for limited LS (morphea) are extragenital lichen 
sclerosus and acrodermatitis chronica atrophicans, for generalized LS chronic graft versus host 
disease, SSc, and nephrogenic systemic fibrosis, and for linear LS lupus erythematosus 
profundus and other types of panniculitis. All differential diagnoses with respect to LS subtypes 
and stage of disease are summarized in Table 3. 
 
<TABLE 3> 
 
Specifics of juvenile localized scleroderma 
Whereas limited types of LS most commonly occur in adults, linear subtypes predominate in 
children. A study including 65 patients with juvenile LS revealed that linear subtypes may 
follow the lines of Blaschko. It was hypothesized that in linear LS, susceptible cells are present 
in a mosaic state and that exposure to some trigger factors finally result in the initiation of 
disease.27 Clinical course of disease is often more severe in juvenile LS compared with adult 
linear LS, and may lead to considerable atrophy of the skin, fat tissue, fascia, and muscle. This 
might finally result in substantial functional, physical, and mental disability. It has been shown 
that 30–50% of patients with linear LS experience osteoarticular complications (e.g. arthritis) 
on the affected extremity.49–51 Both linear LS “en coup de sabre” and progressive facial 
hemiatrophy mainly occur in childhood. It seems that both conditions belong to the same 
spectrum of disease, with overlapping clinical features. In contrast to other subtypes of LS, 
linear LS “en coup de sabre” and progressive facial hemiatrophy have a more insidious clinical 
course, and the active stage of disease persists usually longer than in other subtypes of LS. 
Neurologic symptoms are frequent and may include epileptic seizures, neuropsychiatric 
symptoms, headaches, and mental or behavioral disorders.28,52,53 Ophthalmologic changes are 
common in juvenile LS and might manifest as uveitis, dysfunction of the eye muscles, and loss 
of eyebrows or eyelashes. 
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“Disabling pansclerotic morphea,” a rare subtype of generalized LS, usually manifests before 
the age of 14, and is obligatorily associated with affection of extracutaneous structures. It 
frequently results in disturbance of growth and cachexia.  
 
Abnormal blood findings are frequent in juvenile LS. In the active stage of generalized LS, 
blood eosinophilia is frequent. Moreover, an elevated rheumatoid factor, increased blood 
sedimentation rate, hypergammaglobulinemia (increased IgA and IgM in active stages of LS 
and increased IgG in severe disease with contractures), as well as elevated antinuclear, anti-
histone, and single-stranded DNA antibodies might be present.54 
 
In order to prevent persistent damage, effective systemic therapy should be initiated in the 
active stage of all linear types of juvenile LS as early as possible. Similarly to adult LS, subtype 
and extent of disease have an influence on the respective therapy. Concomitant physiotherapy 
should be considered in subtypes with (potential) restriction of motion. Surgical interventions 
should only be performed in the inactive stage of disease.55 The same is true for aesthetic-
reconstructive interventions in linear LS “en coup de sabre” and progressive facial hemiatrophy. 
 
Treatment 
Although no causal treatment for LS exists, a variety of therapeutic options are available, 
especially for the active phase of disease. In general, treatment options for LS might be divided 
into topical and systemic therapy as well as ultraviolet (UV) phototherapy. The extent and 
severity of LS should be taken into account before initiating the respective therapy. For 
example, topical and UV phototherapy are usually appropriate in limited types of LS that are 
restricted to the skin, whereas generalized, linear or deep types usually require systemic 
treatment. Hereafter, all treatment options that have been reported for LS are summarized. 
Moreover, a treatment algorithm is provided that incorporates the subtype, severity, and extent 
of LS (Fig. 1). When evaluating the treatment efficacy it should be remembered that reduction 
of skin sclerosis starts 8–12 weeks after initiation of therapy, at the earliest. None of the 
therapies mentioned below are officially licensed in Europe.  
 
<FIG. 1> 
 
Topical therapy 
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Topical glucocorticoids 
Although no well-performed studies exist on the use of topical glucocorticoids, they are the 
mainstay of topical treatment in LS. Therapy with moderate-to-high potent glucocorticoids 
should be performed in the active phase of disease, and their application should be restricted to 
a total of 3 months. Longer application of topical glucocorticoids should be given as interval 
therapy. In order to increase the efficacy, an application under occlusion might be considered. 
Intralesional glucocorticoid therapy might be performed in LS “en coup de sabre,” with 
injections into the active margin.  
 
Topical calcipotriol 
To date, two uncontrolled studies have been conducted on the use of topical calcipotriol in LS, 
one of which administered calcipotriol 0.005% along with low-dose UVA1 phototherapy.56 In 
both studies, administration was performed twice daily. In the monotherapy study, calcipotriol 
0.005% was applied under occlusion.57  
 
Calcipotriol 0.005% should be considered for active inflammatory superficial types of LS with 
a low degree of sclerosis. Treatment should be performed twice daily (under occlusion) for a 
minimum of 3 months. 
 
Topical calcineurin inhibitors 
Following two open studies on topical tacrolimus 0.1% ointment in LS, a recent double-blind, 
placebo (petroleum emollient)-controlled pilot study has shown that topical tacrolimus 
significantly improves LS.58–60 Outcome measures in this study were the changes of surface 
area, a clinical score for erythema, induration, dyspigmentation, telangiectasia, atrophy, and a 
durometer score.58 Early inflammatory lesions resolved and late sclerotic lesions softened, 
whereas no effects were seen on pre-existing skin atrophy.  
 
Thus, tacrolimus ointment might be an effective treatment option for active LS lesions. To date, 
no studies on pimecrolimus for LS have been conducted. 
 
Imiquimod 
In case reports and small case series, the topical immune response modifier imiquimod has been 
reported to significantly improve abnormal pigmentation, sclerosis, and erythema in LS.61–63 
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The mechanism of imiquimod action in LS might be explained by induction of interferon-γ 
which inhibits TGF-β, thereby possibly exhibiting a broad anti-fibrotic effect.  
 
However, based on these small case series, imiquimod cannot be recommended for LS until 
more valid data are available.  
 
Intralesional interferon-γ 
A double-blinded, placebo-controlled trial demonstrated no significant improvement of 
intralesional interferon-γ compared with the placebo group. Accordingly, intralesional 
interferon-γ cannot be recommended for the treatment of LS.64 
 
Systemic therapy 
Systemic glucocorticoids 
Similarly to topical gucocorticoids, there is a paucity of data on systemic glucocorticoids, 
although they are widely used agents in LS, particularly in linear, generalized, and deep 
subtypes. In the only published uncontrolled study on 17 patients with LS (glucocorticoid 
dosage: 0.5–1.0 mg/kg body weight daily), a marked improvement was noticed in nearly all of 
the patients.65 However, about one third of patients experienced recurrences after finishing 
therapy. Systemic gucocorticoids are safe and effective in active lesions of LS, and should be 
considered in patients with severe disease, especially in those forms affecting extracutaneous 
structures (e.g. fat tissue, fascia, muscle, and bone). Moreover, systemic glucocorticoids are the 
first-line treatment option in eosinophilic fasciitis.66 Treatment should be planned for a 
sufficient duration, as clinical effects are sometimes seen at the earliest 3 months after onset. 
 
Methotrexate 
Among systemic treatment of LS, best evidence exists for the use of methotrexate. To date, one 
placebo-controlled multi-center trial, as well as three prospective and four retrospective studies 
have been published.49,67–73 In the placebo-controlled study, a total of 70 children with active 
LS (46 patients in the methotrexate group and 24 in the placebo group) were included to receive 
methotrexate orally (15 mg/m², maximum 20 mg) or placebo. Moreover, oral prednisone 
(1 mg/kg/day, maximum 50 mg) was added in both arms for 3 months. The computerized 
scoring system, as well as infrared thermography were used as outcome measures. In both arms, 
a reduction of the clinical score was observed within the first 6 months. However, at the end of 
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the study at month 12, a significant decrease of the clinical score as well as infrared 
thermography was only observed in the methotrexate group.67  
 
In the three prospective studies that included 34 patients (24 adults and 10 children), a 
combination of high-dosage intravenous methylprednisolone and methotrexate (adults 
15 mg/weeks; children 0.3 mg /kg/week) was used, and outcome measures were a non-
validated clinical score and ultrasound scanning. All adults and nine of the 10 children 
experienced a significant improvement under therapy.49,68,69 In the four retrospective studies, a 
total of 119 patients were included (52 patients with methotrexate monotherapy and 67 patients 
with a combination of methotrexate and systemic glucocorticoids). In 97% of patients, a clinical 
improvement was observed.70–73 Importantly, it was shown in another study that 28% of patients 
with juvenile LS experienced a relapse after treatment with methotrexate.74  
 
In the studies mentioned above, different dosages of methotrexate and systemic glucocorticoids 
were used. In 2012, the “Childhood Arthritis and Rheumatology Research Alliance” (CARRA) 
recommended three different treatment regimens for juvenile LS: 1) methotrexate 
monotherapy; 2) pulse methotrexate and glucocorticoid therapy with methylprednisolone given 
intravenously; 3) pulse methotrexate and glucocorticoid therapy with prednisone given orally.75 
These recommendations have been incorporated in the treatment algorithm (Fig. 1) of this 
guideline.     
 
Mycophenolate mofetil 
In 2009, a small case series of seven methotrexate-resistant LS patients treated with 
mycophenolate mofetil (MMF) showed improvement of skin sclerosis and inflammation, as 
documented with infrared thermography and clinical scoring.76,77 In vitro studies have shown 
that MMF inhibits the proliferation of lymphocytes, but also of other cell types, including 
smooth muscle cells and fibroblasts, indicating that it has direct anti-fibrotic properties in 
addition to its well-known immunosuppressive effects.78 These preliminary observations make 
MMF an interesting new candidate for further clinical studies. According to CARRA, MMF 
should be considered as a second-line therapy if methotrexate has failed. It is noteworthy that 
in several countries (e.g. Germany) health insurers sometimes deny re-imbursement for this off-
label use. 
 
Calcitriol 
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A randomized controlled study that included 20 patients with LS demonstrated that a 9-month 
therapy with oral calcitriol (0.75 µg/daily for 6 months, followed by 1.25 µg/daily for 
3 months) failed to achieve any significant improvement compared with placebo.79 Therefore, 
oral calcitriol cannot be recommended for LS.   
 
D-penicillamine 
Although the efficacy of D-penicillamine has been reported in a small case series of LS patients, 
no significant differences were found between high-dose (750–1000 mg daily) and low-dose 
therapy (125 mg daily) in SSc.80,81 Given the poor evidence level of efficacy and the 
problematic side-effect profile of D-penicillamine, it cannot be recommended for the treatment 
of LS. 
 
Penicillin 
For decades penicillin has been used for the treatment of LS because LS can manifest after an 
infection with Borrelia. Although penicillin has anti-inflammatory properties, direct anti-
fibrotic effects have so far not been demonstrated. Accordingly, the efficacy of penicillin in LS 
remains unproven.   
 
Miscellaneous 
Numerous other systemic therapies have been used in cases of LS, including cyclosporine, 
azathioprine, chloroquine and hydroxychloroquine, phenytoin, colchicine, retinoids, 
extracorporeal photopheresis, plasmapheresis, intravenous immunoglobulin, abatacept, 
infliximab, rituximab, and imatinib.82–87 These treatments should be reserved for single severe 
cases with contraindications or failure to standard therapy.   
 
UV phototherapy 
Within the last two decades, the vast majority of clinical studies on LS came from the field of 
photodermatology.88 One of the rationales for using UV phototherapy in sclerotic skin diseases 
is the fact that UV can induce interstitial MMP.89,90 The first experience of the successful use 
of UV phototherapy in LS was in 1994.91 Since then, much information has been gained on the 
entire spectrum of anti-fibrotic and anti-inflammatory effects of UV phototherapy in skin 
sclerosis.92 In addition, UV phototherapy leads to apoptosis of dermal T cells, depletion of 
Langerhans cells, and to modulation of several pro-inflammatory cytokines.88 The exact 
mechanism of action of UV therapy in sclerotic skin diseases remain to be determined. Because 
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longer wavelengths in the UVA range (320–400 nm) penetrate deeper into the dermis compared 
with UVB (280–320 nm), most studies have focused on UVA. Before initiating UV 
phototherapy in LS, it should be considered that UV rays only penetrate into the deep dermis. 
Therefore, UV phototherapy (in combination with topical treatment, e.g. topical glucocorticoids 
or topical vitamin D analogs) is an effective treatment option for limited disease restricted to 
the skin, but not in LS subtypes affecting deeper structures (e.g. fat tissue, fascia, muscle, or 
bone). Such subtypes require systemic therapy. However, it is also known that UV can act 
indirectly by modulating cytokine release in keratinocytes.  
 
UV irradiation has a major role in the pathogenesis of skin cancer due to its capacity to induce 
immunosuppression and DNA damage. However, the dosages and duration of UVA irradiation 
used in the treatment of sclerotic skin diseases are most likely too low to induce any significant 
skin damage, though there may be an absolute safe threshold dose.93  
 
PUVA phototherapy 
In order to avoid the well-known side effects of oral application of 8-methoxypsoralen, psoralen 
combined with UVA (PUVA) was mainly applied in LS as bath PUVA phototherapy. Besides 
several case reports, two retrospective case series exist on bath PUVA phototherapy.94,95 In the 
larger study published in 2013, 28 patients were treated with bath PUVA three times per week. 
In 39% of patients, a complete clearance of all lesions was observed, 50% experienced clinical 
improvement, and 10% had no response.95 Moreover, a small case series of four patients treated 
with cream PUVA phototherapy showed similar encouraging results.96 PUVA phototherapy is 
usually performed 2–3 times per week for a total of 30 irradiations.  
 
Broadband UVA 
Three prospective studies have been published on the use of broadband UVA (320–400 nm) in 
LS. Among those, the largest study included 63 patients.97–99 The three dosages used in this 
study (5, 10, and 20 J/cm² for a total of 20 irradiations each) showed similar efficacy. Controlled 
studies comparing broadband-UVA with other UV modalities are lacking. 
 
UVA1 phototherapy 
In the area of phototherapy, the most robust data exist for UVA1. Three different dosages of 
UVA1 can be distinguished: low-dose UVA1 (10–29 J/cm²), medium-dose UVA1 (30–
59 J/cm²), and high-dose UVA1 (60–130 J/cm²). All regimens have been used in LS, and the 
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first report was published in 1991.100 The first prospective study on UVA1 phototherapy in LS 
demonstrated that high-dose UVA1 is highly effective, but low-dose UVA1 failed to show any 
substantial effects in LS.101 Nevertheless, several prospective studies performed some years 
later showed that low-dose and medium-dose UVA1 are effective as well.56,102–108 To date, only 
one randomized controlled study has been performed that compared low-dose UVA1, medium-
dose UVA1, and narrow-band UVB phototherapy in a collective of 64 LS patients. All three 
UV regimens significantly improved the skin scores, with medium-dose UVA1 being 
significantly better than narrow-band UVB.109 Whether patients with darker skin respond less 
to UVA1 phototherapy is still a matter of debate.110,111 Moreover, it has been shown that within 
3 years, about 50% of patients treated with UVA1 experience recurrences after therapy.112 In 
these cases, a second cycle of UVA1 phototherapy should be considered. UVA1 is usually 
performed 3–5 times per week for a minimum of 30 irradiations. 
 
Physiotherapy 
Studies on physiotherapy in LS are lacking. Nevertheless, physiotherapy is an important 
component in the multimodal treatment concept for LS, and is frequently performed in daily 
practice. In particular, linear, generalized, deep, and mixed types of LS should be treated with 
physiotherapy. It should not be performed in the active, inflammatory stage of disease. Massage 
and lymphatic drainage can be added to systemic therapy in patients with sclerotic stage disease. 
Physiotherapy is usually performed once or twice per week for at least 3 months.  
 
Surgical therapy 
Surgical therapy is predominantly indicated in linear types of LS. It is important that surgical 
interventions are only considered in the inactive stage of disease in order to minimize the risk 
of reactivation. If signs for disease activity occur, perioperative immunosuppressive therapy 
should be considered. In linear LS of the limbs, epiphysiodesis of the healthy extremity can be 
considered in order to adjust leg length inequality. This procedure should be performed by an 
experienced pediatric orthopedist.  
 
Plastic surgical interventions might be considered for cosmetic reasons in linear LS “en coup 
de sabre” or progressive facial hemiatrophy.  
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Table 1 Classification of localized scleroderma/morphea* 
Limited type 
• Plaque-morphea (single or multiple lesions) 
• Guttate morphea 
• Atrophoderma idiopathica of Pierini and Pasini (superficial morphea) 
 
Generalized type 
• Generalized localized scleroderma/morphea 
• Disabling pansclerotic morphea 
 
Linear type 
• Linear localized scleroderma/morphea of the extremities 
• Linear localized scleroderma/morphea “en coup de sabre” 
• Progressive facial hemiatrophy (Parry–Romberg syndrome) 
 
Deep type 
• Deep morpheaa 
 
Mixed typeb 
 
Eosinophilic fasciitis (Shulman syndrome)c 
*According to the German guideline for the diagnosis and treatment of localized scleroderma.1 All types of LS 
may present with overlapping features of other types (e.g. generalized types with linear or deep aspects). 
aDeep type of localized scleroderma (LS) and deep morphea are synonymous. 
bMixed types of LS predominantly affect children and often consist of linear LS and morphea (plaques type of 
LS) or a combination of linear and generalized LS. 
cThe authors consider eosinophilic fasciitis as a separate subtype that belongs to the spectrum of LS. 
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Table 2 Laboratory parameters in localized scleroderma 
Blood differential 
• Important in linear types of LS and in eosinophilic fasciitis because of eosinophilia) 
 
Clinical chemistry 
• Transaminases (aspartate aminotransferase and alanine transaminase) – elevated transamninases are seen in 
myositis 
• Cholestasis parameters (γ-glutamyltransferase and alkaline phosphatase) – to uncover biliary cirrhosis 
• Lactate dehydrogenase  
• Creatinine 
• Creatine kinase – especially in cases of suspected concomitant myositis 
• Blood sedimentation rate and C-reactive protein 
 
Additional diagnostics 
• Screening for antibodies against extractable nuclear antigens – only to confirm/exclude systemic sclerosis (e.g. 
with anti-scl-70 or anti-centromere antibodies); anti-histone antibodies are often detectable in linear types that 
affect the extremities in children) 
 
LS, localized scleroderma. 
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Table 3 Differential diagnoses of localized scleroderma* 
 
Initial inflammatory phase in limited localized scleroderma (morphea) 
• Lichen sclerosus 
• Erythema chronicum migrans 
• Cutaneous mastocytosis 
• Granuloma annulare 
• Radiation dermatitis 
• Mycosis fungoides 
• Drug-related reactions 
• Chronic radiation dermatitis 
Late stage in limited localized scleroderma (morphea) mainly with hyperpigmentation 
• Post-inflammatory hyperpigmentation 
• Lichen planus actinicus 
• Café-au-lait spots 
• Erythema dyschromicum perstans 
Late stage in limited localized scleroderma (morphea) mainly with atrophy 
• Acrodermatitis chronica atrophicans 
• Lipodystrophy 
• Lichen sclerosus 
• Scarring 
Late stage in limited localized scleroderma (morphea) mainly with sclerosis 
• Necrobiosis lipoidica 
• Pretibial myxedema 
Generalized localized scleroderma 
• Systemic scleroderma 
• Pseudoscleroderma 
• Scleredema adultorum (Buschke’s disease) 
• Scleromyxedema 
• Chronic graft versus host disease 
• Mixed connective tissue disease 
• Nephrogenic systemic fibrosis, also known as nephrogenic fibrosing dermopathy 
• Porphyria cutanea tarda 
Linear localized scleroderma, “en coup de sabre” 
• Panniculitis 
• Progressive lipodystrophy 
• Localized lipodystrophy (e.g. lipodystrophia centrifugalis abdominalis infantilis) 
• Focal dermal hypoplasia 
• Steroid atrophy 
• Lupus erythematosus profundus 
 
*According to the German guideline for the diagnosis and treatment of localized scleroderma.1 
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Figure 1 Treatment algorithm for localized scleroderma depending on the clinical subtype and extent of disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In localized scleroderma subtypes with limited skin involvement that do not adequately respond to topical or phototherapy, systemic therapy should be considered. The dosages 
and treatment schedules on UVA1 phototherapy and PUVA might also be used in other sclerotic diseases (e.g. sclerotic skin in systemic sclerosis).  
Localized scleroderma 
Subtype with limited skin involvement 
(reaching to the dermis) 
Subtype with severe skin and/or musculoskeletal 
involvement (affecting fat tissue, fascia, muscle, 
joints, and bones, or widespread skin involvement) 
Alternatively: 
Topical calcipotriol (alone 
or combined) or topical 
calcineurin inhibitor, 
1–2 daily 
Topical glucocorticoids: 
High potent (e.g. clobetasol) up to 
1 month once daily, 
or 
Mid-potent (e.g. mometasone 
furoate) up to 3 months once daily 
 
A longer therapy with 
glucocorticoids should be given as 
‘interval treatment’ 
PUVA therapy 
Oral, bath, or cream, 
depending on extent of 
disease, 2–4/week, 
min. of 30 UV irradiations 
UVA1 phototherapy 
50–80 J/qcm, 3–5/week, 
min. of 30 UV irradiations 
Systemic glucocorticoids 
IV: 500–1000 mg methylprednisolone/day for 
3 consecutive days/month, up to 3–6 months 
or 
Oral: 0.5–2.0 mg prednisolone/kg body 
weight/day, for 2–4 weeks max., tapering of 
dosage thereafter 
Systemic glucocorticoids 
IV: 30 mg methylprednisolone/kg body weight 
(max. 1000 mg)/day for 3 consecutive days, 
for a total of at least 3–6 months 
or 
Oral: 0.5–2.0 mg prednisolone/kg body 
weight, preferably divided into 2–3 dosages 
daily (max. 60 mg) for 2–4 weeks max., 
tapering of dosage thereafter 
and/or and/or 
Methotrexate 
12.5–25 mg/week 
Methotrexate 
15 mg/qm BSA/week 
max. 25 mg/week 
Adults Children Duration of therapy 
should be at least 
12 months, depending 
on the efficacy, 
tapering of dosage 
should be considered 
To increase the 
effects, an occlusive 
application can be 
considered 
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II  Scleromyxedema  
 
Introduction  
Scleromyxedema, also known as generalized and sclerodermoid lichen myxedematosus or 
Arndt–Gottron disease, is a primary cutaneous mucinosis characterized by a generalized 
papular and sclerodermoid cutaneous eruption that usually occurs in association with 
monoclonal gammopathy.1,2 Affected patients develop numerous waxy firm papules and 
plaques that demonstrate mucin deposition, increased fibroblast proliferation, and fibrosis on 
histologic examination. Systemic manifestations may involve the cardiovascular, 
gastrointestinal, pulmonary, musculoskeletal, renal, or nervous systems, and may lead to 
significant morbidity and mortality. 
 
Epidemiology 
Scleromyxedema is a rare disease that usually affects middle-aged adults between the ages of 
30 and 80 years with no race or sex predominance.3 In a multicenter retrospective study of 30 
patients with scleromyxedema, the mean age of affected patients was 59 years.3 This illness has 
rarely been reported in infants and young children. 
 
Pathogenesis 
The pathogenesis of scleromyxedema is unknown. The true significance of the associated 
monoclonal gammopathy and the underlying plasma cell clone is unclear. The main hypothesis 
is that circulating cytokines such as interleukin (IL)-1, tumor necrosis factor (TNF)-alpha, and 
transforming growth factor (TGF)-beta, which are known to stimulate glycosaminoglycan 
synthesis and fibroblast proliferation in the skin, could play a role.1,2,4 Clinical remission of 
scleromyxedema following autologous stem cell transplantation suggests that the bone marrow 
may be a source of these circulating factors.5 
 
However, paraprotein levels usually do not correlate with the severity of disease, disease 
progression, or the response to treatment.3 Only on an anecdotal basis has the complete 
resolution of skin lesions coincided with the normalization of the bone marrow and the 
disappearance of the paraprotein.6 
 
Clinical manifestation  
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The clinical manifestations of scleromyxedema include both cutaneous and extracutaneous 
features. 
 
Cutaneous manifestations 
The characteristic skin finding in scleromyxedema is a widespread eruption of 2 to 3 mm, firm, 
waxy, closely-spaced, dome-shaped or flat-topped papules involving the hands, forearms, head, 
neck, upper trunk, and thighs. Papules are often arranged in a strikingly linear array and the 
surrounding skin is shiny and indurate (i.e. sclerodermoid) in appearance. Rarely, non-tender 
subcutaneous nodules are present. The glabella is typically involved with deep, longitudinal 
furrows that produce a characteristic leonine face. Deep furrowing is also typically evident on 
the trunk or limbs and is called the “Shar-Pei sign.” Erythema, edema, and a brownish 
discoloration may be seen in the involved areas; pruritus is not uncommon. 
 
Eyebrow, axillary, and pubic hair may be sparse in patients with scleromyxedema. The mucous 
membranes are spared. As the condition progresses, erythematous and infiltrated plaques may 
appear with skin stiffening, sclerodactyly, and decreased motility of the mouth and joints. On 
the proximal interphalangeal joints, a central depression surrounded by an elevated rim (due to 
skin thickening) can be seen and is referred to as the “doughnut sign.” Unlike scleroderma, 
telangiectasias and calcinosis are absent and the Raynaud’s phenomenon occurs rarely. 
 
Extracutaneous manifestations 
Patients with scleromyxedema can have systemic manifestations, including neurologic, 
rheumatologic, cardiovascular, gastrointestinal, pulmonary, and renal manifestations of the 
disease. In a multicenter retrospective study of 30 patients with scleromyxedema, the most 
common extracutaneous manifestations were neurologic abnormalities (30% of patients), 
rheumatologic abnormalities (25% of patients), and cardiac abnormalities (22% of patients).3 
 
Neurologic 
Neurologic symptoms may involve the peripheral nervous system (e.g. carpal tunnel syndrome 
or peripheral sensory and motor neuropathy). Carpal tunnel syndrome is thought to be due to 
either deposition of glycosaminoglycans in the carpal tunnel or to a direct toxic effect in the 
median nerve.7 The central nervous system (CNS) can also be involved (e.g. memory loss, 
vertigo, gait problems, stroke, seizures, psychosis).8,9 The dermato-neuro syndrome is a rare, 
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and potentially lethal (acute neurologic complication characterized by fever, confusion, 
dysarthria, lethargy, convulsions, and coma).9,10 
 
Rheumatologic 
Rheumatologic manifestations are characterized by arthralgia or arthritis of the peripheral 
joints, especially of the hands, with non-inflammatory synovial fluids.11 A severe destructive 
polyarthritis resembling rheumatoid arthritis has also been reported.12 Proximal or generalized 
weakness due to inflammatory myopathy and fibromyalgia is common and usually occurs 
several months or years after the onset of skin involvement.4,13 In these patients, muscle biopsy 
reveals a necrotizing and vacuolar myopathy; interstitial inflammatory infiltrates are found 
uncommonly and may cause confusion with polymyositis. A few cases of true dermatomyositis 
have been described in association with scleromyxedema.14 Spontaneous or interferon alfa-
induced rhabdomyolysis is an additional rare finding.15,16 
 
Cardiovascular 
Cardiovascular abnormalities with congestive heart failure, myocardial ischemia, heart block, 
and pericardial effusion may occur.3,17,18 Valvular myocardial mucin deposition has been 
described in a case report.19 
 
Gastrointestinal 
Dysphagia is the most common gastrointestinal manifestation and is related to esophageal 
dysmotility mainly localized to the upper esophagus.20 Dysphagia is most commonly found in 
patients with an associated myopathy. Nasal regurgitation may also occur.20 
 
Respiratory 
Dyspnea on exertion is the most common pulmonary finding, due to obstructive or restrictive 
pathology.20–22 In addition, hoarseness and aspiration may occur due to laryngeal involvement 
with decreased epiglottis and vocal cord mobility.23 
 
Renal 
Involvement of the kidney, characterized by a scleroderma renal crisis-like acute renal failure, 
is a rare event.24 
 
Ocular 
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Infrequently, corneal opacities and ectropion are seen. 
 
Associated disorders 
Scleromyxedema is associated with paraproteinemia. The monoclonal gammopathy is usually 
IgG with a predominance of lambda light chains over kappa light chains.3,20,21 Less frequently, 
a different paraproteinemia is detected. In a retrospective study of 26 patients with 
scleromyxedema evaluated at a single academic center between 1966 and 1990, alternative 
paraproteinemias were detected in three patients (IgM-kappa, IgA-kappa, or IgA-lambda), and 
a further three patients had no evidence of a paraproteinemia.20 Patients with scleromyxedema 
in the absence of paraproteinemia are considered to have an atypical form of the disease. 
 
A mild plasmacytosis may be found in the bone marrow of patients with scleromyxedema. 
However, the disease is estimated to progress to multiple myeloma in less than 10% of cases.4 
Anecdotal associations with hematologic malignancies (such as Hodgkin and non-Hodgkin 
lymphomas, Waldenström’s macroglobulinemia, and myelomonocytic leukemia) or visceral 
carcinomas have been reported;3,25–27 however, no clear association with any specific non-
iatrogenic neoplasm has been identified. Most malignancies in these patients are iatrogenic and 
associated with the use of melphalan treatment.20 
 
Clinical course 
Scleromyxedema follows a chronic, progressive, and sometimes unpredictable course.2 
Depending on the rapidity of onset and the degree of involvement, patients may be either 
initially asymptomatic or may notice that skin becomes thick and hard, and that the face shows 
a diffuse induration and coarsening in the forehead lines and in lateral portions of the chin. As 
the disease progresses (usually over the course of years and occasionally over the course of 
several months), a diffuse sclerodermoid induration with overlying papules, sclerodactyly, and 
decreased motility of the mouth and joints occurs. Our experience suggests that spontaneous 
resolution does not occur; however, at least one case of apparent spontaneous resolution has 
been reported.28 
 
Systemic consequences of scleromyxedema may result in death.3 In a case series in which 
follow-up was available for 21 patients with scleromyxedema (mean follow-up time 
33.5 months, range 2 months to 11 years), at the end of follow-up, five patients died (23.8%), 
whereas 12 patients were alive with disease and four patients were alive without disease.3 Death 
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was caused by extracutaneous complications of scleromyxedema including dermato-neuro 
syndrome (two patients) and myocardial insufficiency due to endocardial mucin deposition (one 
patient) or by an associated myeloid leukemia (one patient) or Hodgkin lymphoma (one 
patient).  
 
Diagnostic procedures 
Histopathology  
Scleromyxedema is characterized by a triad of microscopic features that includes:29,30 
• a diffuse deposit of mucin composed primarily of hyaluronic acid in the upper and mid-
reticular dermis; the presence of mucin can be confirmed with an Alcian blue stain (pH 
2.5) or a colloidal iron stain and hyaluronidase digestion; 
• an increase in collagen deposition; 
• a marked proliferation of irregularly arranged fibroblasts. 
 
A rare interstitial, granuloma annulare-like pattern has been described in cutaneous biopsy 
specimens from patients with scleromyxedema.31 This histologic pattern is characterized by a 
diffuse, interstitial proliferation of blue-gray histiocytes, giant cells, and lymphocytes within 
the papillary and mid-reticular dermis forming loose granulomas among collagen fibers and 
mucin deposits. 
 
Histologic specimens from extracutaneous sites may demonstrate mucin filling endocardium 
walls of myocardial blood vessels as well as the interstitium of the kidney, lungs, pancreas, 
adrenal glands, and nerves.18 Lymph node involvement with infiltration by numerous 
fibroblasts surrounded by mucin and collagen deposits has been observed.32 
 
The diagnosis of scleromyxedema is based upon the recognition of the following 
clinicopathologic criteria: 
• generalized papular and sclerodermoid eruption; 
• microscopic triad, including mucin deposition, fibrosis, and fibroblast proliferation; 
• monoclonal gammopathy; 
• absence of thyroid disorder. 
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Atypical forms of scleromyxedema include scleromyxedema in the absence of monoclonal 
gammopathy or scleromyxedema demonstrating an interstitial granulomatous-like pattern on 
histopathology. 
 
Differential diagnosis 
The major disorders to be considered in the differential diagnosis of scleromyxedema are 
localized scleroderma (LS), systemic scleroderma (systemic sclerosis [SSc]), scleredema, and 
nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy (NSF, NFD).33 
 
Scleroderma 
Although patients with scleromyxedema may have symptoms that mimic scleroderma, such as 
sclerodactyly, the Raynaud’s phenomenon (rarely), and esophageal dysmotility, clinical and 
laboratory features distinguish the two diseases. The presence of diffuse, waxy papules in linear 
arrays and in a characteristic distribution that includes the glabella and posterior auricular area, 
the involvement of the middle portion of the back (always spared in scleroderma), and the 
presence of an IgG monoclonal gammopathy all favor a diagnosis of scleromyxedema. 
Histologically, dermal mucin deposition is absent in LS and SSc. 
 
Scleredema 
The histologic findings of scleromyxedema and scleredema differ. The fibroblast proliferation 
that is evident in histologic specimens of scleromyxedema is absent in scleredema, whereas 
scleredema shows increased thicknes of the dermis and deeper collagen deposition with mucin 
deposition in the spaces (fenestrations) between collagen bundles. 
 
Nephrogenic systemic fibrosis/dermopathy 
NSF and NFD can have a similar histologic appearance to scleromyxedema, with findings of 
mucin and fibroblastic proliferation in biopsy specimens. Clinical correlation is useful for 
distinguishing the two diseases. Unlike scleromyxedema, facial involvement (common in 
scleromyxedema), and monoclonal gammopathy are not features of nephrogenic systemic 
fibrosis. Further details for NSF can be found in section IV of this guideline. 
 
Localized lichen myxedematosus 
In localized lichen myxedematosus the following features of scleromyxedema are absent: 
sclerotic features, systemic involvement, and monoclonal gammopathy. In the past, the terms 
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“papular mucinosis,” “lichen myxedematosus,” and “scleromyxedema” were often used 
indiscriminately. Although scleromyxedema and the localized type of lichen myxedematosus, 
including subtypes such as acral persistent papular mucinosis, discrete lichen myxedematosus, 
papular mucinosis of infancy, and nodular lichen myxedematosus, belong to the same disease 
spectrum, it is important to make a distinction between the two disorders because of differences 
in prognosis and the approach to therapy.1,2 Historically, most patients reported in the literature 
to have lichen myxedematosus or papular mucinosis without specification of the disease 
subtype appear to have had scleromyxedema with monoclonal gammopathy. Occasionally, 
patients have overlapping or atypical features and fall in between scleromyxedema and 
localized lichen myxedematosus.2 
 
Treatment  
No randomized trials have evaluated therapies for scleromyxedema, and data are primarily 
limited to case reports and case series due to rarity of the disease. No specific treatment appears 
to be uniformly effective, and the relative efficacies of the treatments that have been utilized 
remain unclear. 
 
First-line therapy 
Systemic therapy is the treatment method of choice for patients with scleromyxedema. Case 
reports and case series have documented improvement in the cutaneous and extracutaneous 
signs and symptoms of scleromyxedema during intravenous immunoglobulin (IVIg) therapy, 
with a generally favorable tolerability profile.3,34 IVIg should furthermore be considered the 
treatment of choice in refractory cases of scleromyxedema with either fast deterioration of skin 
symptoms, the dermato-neuro syndrome, or life-threatening involvement of internal organs. 
  
Initial duration of treatment 
As with the other conditions, the use of IVIg is initially recommended over a period of 
6 months. If there is no response to treatment after this time, treatment should be discontinued. 
 
Interval between infusions 
The initial interval between infusions should be 4 weeks. The interval between the individual 
bolus infusions can then be increased gradually to 6 weeks. Any additional increase in the 
interval is not recommended, as the half-life time of IVIg is about 21 days. 
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Dosing 
Most experience in scleromyxedema exists with the standard dose of 2 g per kg body weight. 
This should be adopted as the standard recommendation. 
 
Treatment period 
Treatment should be administered over a period of 2 days. In the case of severe organ 
involvement, such as kidney or heart involvement in particular, or in patients at risk of renal 
involvement, with concomitant diuretics, diabetes, hypertension, obesity or in elderly patients, 
the treatment period should be increased to 5 days. 
 
Evaluation of treatment efficacy 
The focus lies on the clinical evaluation of treatment efficacy. As skin involvement is present 
in nearly all cases and responds very well to treatment with IVIg, it should be used as an 
indicator of response. Therefore re-evaluation after three cycles is recommended. In isolated 
cases, clinical response to CNS or internal organ involvement can be used as an additional 
indicator of response in scleromyxedema. 
 
Long-term therapy 
Relapse has been documented in several cases after discontinuation of IVIg. If a relapse is 
severe or life-threatening, long-term therapy can be recommended in exceptional cases.3,35–37 
 
The mechanism through which IVIg improves scleromyxedema is unclear. Suggested 
mechanisms underlying the immunomodulatory effects of IVIg include neutralization of 
circulating autoantibodies by anti-idiotype antibodies, functional blockade and modulation of 
Fc fragment receptors at the surface of macrophages, and inhibition of fibrosis via modulation 
of the production of cytokines and cytokine antagonists.38 
 
Side-effects 
Drawbacks of IVIg treatment are its high cost and the time-consuming administration. IVIg 
treatment is well tolerated. Side-effects such as skin rash, arthralgia, myalgia, fever, headache, 
thoracic or abdominal pain, nausea, and tachycardia may occur. Severe adverse events related 
to IVIg treatment are rare and include anaphylactic shock in patients with IgA deficiency and 
anti-IgA antibodies, renal insufficiency in at-risk patients, aseptic meningitis, hemolytic 
anemia, and thrombosis. Myocardial ischemia and death secondary to suspected myocardial 
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infarction39 have been reported in scleromyxedema patients with known cardiac risk factors 
during treatment with IVIg. However, the side-effects experienced by patients receiving IVIg 
for scleromyxedema generally have been mild and self-limiting, and vanish after slowing down 
the infusion rate.  
 
Second-line therapies 
When IVIg treatment is not an option or yields an insufficient response, thalidomide (or 
lenalidomide) and systemic glucocorticoids are the next-line options for treatment. Thalidomide 
and systemic glucocorticoids can be given alone or in combination therapy with IVIg.40–43 
 
Thalidomide 
The mechanism of action of thalidomide in scleromyxedema is unknown. The 
immunomodulatory effects of thalidomide on pro-inflammatory and pro-fibrotic cytokines and 
the antiangiogenic properties of thalidomide may contribute to inhibition of fibrosis. 
 
Treatment with thalidomide should begin at a dose of 50 to 100 mg per day. The dose is slowly 
increased according to clinical response and tolerance up to 150 to 400 mg per day. Once a 
satisfactory response is achieved, the lowest dose effective for maintaining improvement is used 
for maintenance therapy. 
 
Teratogenicity and irreverislble peripheral neuropathy are side-effects of thalidomide that can 
limit the use of this therapy. Patients should be monitored for the development of peripheral 
neuropathy during treatment. In the United States, patient and provider participation in the 
System for Thalidomide Education and Prescribing Safety, a program aimed to prevent the use 
of thalidomide during pregnancy, is required for the use of this medication. Other potential 
adverse effects of thalidomide include drowsiness, constipation, thrombosis, and leukopenia. 
 
A few case reports have documented the use of lenalidomide, a thalidomide derivative with a 
more favorable side-effect profile, for scleromyxedema. Lenalidomide (25 mg per day for 
3 weeks per month) appeared beneficial when used in combination with IVIg.44 
 
Systemic glucocorticoids 
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Systemic glucocorticoids have been used for scleromyxedema in conjunction with 
chemotherapeutic agents or as monotherapy. It is postulated that benefit from systemic 
glucocorticoids may result from immunosuppressive and anti-fibrotic effects of these agents. 
 
Data on the efficacy of systemic glucocorticoids in scleromyxedema are limited to case reports. 
Prednisone (0.5 to 1 mg/kg/day), prednisolone (0.3 to 0.5 mg/kg/day), and oral high-dose 
dexamethasone (40 mg once daily for 4 days per week during three consecutive weeks each 
month) have been associated with improvement in cutaneous manifestations of 
scleromyxedema in individual patients.45–47 The associated paraproteinemia may or may not 
improve in patients in whom systemic glucocorticoid therapy induces remission of 
scleromyxedema. Failure of systemic glucocorticoid therapy to improve scleromyxedema has 
also been reported. 
 
Severe and refractory disease 
Patients who do not improve with the therapies above may benefit from interventions aimed at 
treating the associated plasma cell dyscrasia. Examples of the therapeutic options typically 
reserved for these patients include autologous stem cell transplantation, melphalan, and 
bortezomib with dexamethasone.48 Data are limited on the efficacy of these therapies for 
cutaneous and extracutaneous manifestations of scleromyxedema. In addition, the response to 
these treatments is variable and relapse may occur. Thus, the risks associated with these 
therapies must be considered carefully prior to treatment. 
 
Autologous stem cell transplantation 
Multiple cases of scleromyxedema treated with autologous stem cell transplantation have been 
reported since the initial report of a complete remission in 2001.5 In a review of 17 reported 
cases of scleromyxedema treated with autologous stem cell transplantation published between 
2001 and 2011, complete remission (resolution of all clinical symptoms, skin abnormality, and 
serum paraprotein) was achieved in 10 patients (59%) and partial remission was achieved in 
five patients (29%).49 However, only two of the complete responders remained in remission 
after follow-up periods that ranged from 14 to >60 months. 
 
Melphalan 
Although melphalan was often considered a first-line treatment for scleromyxedema in the past, 
the potential for drug-related serious adverse events limits the use of this agent. A review of 17 
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patients who received melphalan for scleromyxedema (1 to 4 mg per day or cyclic therapy) at 
a single medical center found that although 12 patients had improvement of skin disease with 
therapy, improvement was temporary in eight patients and nine patients died of hematologic 
malignancy or septic complications that were considered to be related to therapy.20 Therefore, 
melphalan is not recommended for scleromyxedema. 
 
Bortezomib and dexamethasone 
Combination therapy with bortezomib and dexamethasone has been associated with rapid 
improvement in cutaneous manifestations and constitutional symptoms of scleromyxedema in 
case reports, including a patient who relapsed after autologous stem cell transplantation.48 
 
Other therapies 
Case reports have documented clinical improvement in patients treated with topical 
betamethasone and topical dimethyl sulfoxide, topical and intralesional glucocorticoid therapy, 
oral isotretinoin, acitretin, interferon-alfa, hydroxychloroquine, cyclosporine, and 
chemotherapeutic agents, including cyclophosphamide, methotrexate, chlorambucil, and 2-
chlorodeoxyadenosine. The efficacies of these agents for scleromyxedema remain to be 
confirmed.  
 
UVA-1 or PUVA phototherapy, Grenz ray, and total skin electron-beam therapy have also been 
reported to improve scleromyxedema in case reports. These therapies do not have an impact on 
paraproteinemia and systemic involvement.  
 
Dermato-neuro syndrome 
The approach to patients with dermato-neuro syndrome is not standardized and various 
treatments have seemed to yield benefit in case reports. Examples include IVIg,50 systemic 
glucocorticoids plus plasmapheresis or IVIg, systemic glucocorticoids plus cyclophosphamide 
and plasmapheresis, melphalan plus IVIg and bortezomib plus dexamethasone.8–10 The most 
suitable choice appears to be IVIg associated with systemic glucocorticoids tapered according 
to the efficacy.    
 
Cosmetic interventions 
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Case reports suggest that facial disfigurement can be treated with dermabrasion plus surgery or 
carbon dioxide laser with good cosmetic results. These procedures do not affect systemic 
manifestations of scleromyxedema. 
 
A treatment algorithm for scleromyxedema is shown in Fig. 1. 
 
Prognosis and follow-up 
Scleromyxedema is a disease with an unpredictable but usually progressive and disabling 
course in the absence of successful treatment. Even when therapy is successful, long-term 
maintenance therapy is usually required as relapse commonly occurs upon the discontinuation 
of treatment. Death may result from complications of extracutaneous involvement or adverse 
effects of therapy. 
 
Because of the various cutaneous and extracutaneous manifestations of scleromyxedema, a 
multidisciplinary team is often needed for the optimal management of these patients. Depending 
on the clinical manifestations, dermatologists, hematologists, cardiologists, pulmonologists, 
gastroenterologists, hand surgeons, and other specialists can be valuable for managing affected 
patients. 
 
The unpredictable course of scleromyxedema, the variable response to treatment, and the 
common occurrence of relapse demand close, long-term follow-up of these patients. We usually 
reassess patients once per month with a full skin examination, review of systems, and re-
evaluation of the therapeutic regimen. Serologic studies, including assessment of the status of 
the associated monoclonal gammopathy, are not useful for monitoring disease activity. 
 
Patients should be cautioned that development of neurologic symptoms (e.g. dysarthria) and 
flu-like illness may be the initial signs of dermato-neuro syndrome. Patients with such 
symptoms should be admitted to the hospital for close observation and evaluation. 
 
 
Summary and recommendations 
• Scleromyxedema is a rare skin disease characterized by generalized papular skin eruptions. 
It is often associated with monoclonal gammopathy and may have accompanying systemic 
48 
features. The disorder typically affects adults. There is no sex predilection. The 
pathogenesis of scleromyxedema is unknown.   
• The cutaneous manifestations of scleromyxedema consist of widespread waxy papules and 
indurated plaques (Table 1). Progressive cutaneous involvement can lead to decreased 
motility of the mouth and joints. Extracutaneous involvement in scleromyxedema can 
present with a variety of manifestations. Neurologic, musculoskeletal, cardiac, 
gastrointestinal, respiratory, or renal abnormalities may develop.   
• The clinical course of scleromyxedema is chronic and progressive. Cutaneous and 
extracutaneous involvement can lead to significant morbidity. Death may result from 
complications related to extracutaneous involvement or adverse effects of therapy.   
• The diagnosis of scleromyxedema is based upon recognition of consistent clinical, 
pathologic, and laboratory findings. The presence of the following features is supportive 
of the diagnosis: 
o generalized papular and sclerodermoid eruption; 
o microscopic triad, including mucin deposition, fibrosis, and fibroblast proliferation; 
o monoclonal gammopathy; 
o absence of thyroid disorder. 
• There are no randomized controlled trials on the treatment of scleromyxedema. The 
available data consist primarily of case reports and case series.   
• Patients with scleromyxedema generally require systemic therapy. High-dose IVIg as 
initial treatment (Grade 2C) is suggested. Thalidomide or other TNF blockers and systemic 
glucocorticoids are alternative treatment options that may also be used in conjunction with 
IVIg therapy. 
• Patients who do not respond to IVIg, thalidomide, TNF blockers, or systemic 
glucocorticoids may benefit from other therapies. Examples of treatment options for severe 
and refractory disease include autologous stem cell transplantation, melphalan, and 
bortezomib plus dexamethasone. The risk–benefit ratios of treatment must be carefully 
considered prior to therapy.   
• Recurrence of scleromyxedema is common after withdrawal of an effective therapy. Long-
term maintenance treatment is usually required, and close clinical follow-up is necessary.   
 
<TABLE 1> 
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Table 1 Scleromyxedema and scleredema overview 
Features Scleromyxedema Scleredema 
Clinical cutaneous A widespread papular eruption 
accompanied by skin induration 
(particularly involving the hands, face), 
and edematous fingers and hands 
Symmetrical diffuse progressive non-
pitting swelling and induration of the 
upper part of the body (especially 
neck, posterior neck, and upper back) 
with occasional erythema 
Clinical 
extracutaneous 
Neurologic, musculoskeletal, cardiac, 
gastrointestinal, respiratory, or renal 
Ocular, tongue, upper part of the 
esophagus, cardiac, pulmonary 
Associated disorders Monoclonal gammopathy Upper respiratory infection, diabetes 
mellitus, or blood dyscrasia  
Histopathology Mucin deposition, fibrosis, and fibroblast 
proliferation in the superficial/mid dermis 
Thickness of dermis with interstitial 
mucin deposition between 
fenestration of collagen without 
fibroblast proliferation 
Diagnosis Generalized papular and sclerodermoid 
eruption 
Microscopic triad, including mucin 
deposition, fibrosis, and fibroblast 
proliferation 
Monoclonal gammopathy 
Absence of thyroid disorder 
Clinicopathologic correlation with a 
non-pitting induration of the upper 
part of the body caused by a thickened 
dermis and deposition of mucin, 
associated with diabetes mellitus or 
with a history of infection or blood 
dyscrasia 
Treatment Intravenous immunoglobulin Usually not required or treat the 
underlying condition 
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Figure 1 Treatment algorithm for scleromyxedema. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Other therapies include topical betamethasone and topical dimethyl sulfoxide, topical and intralesional 
glucocorticoid therapy, oral isotretinoin, acitretin, interferon-alfa, hydroxychloroquine, cyclosporine, and 
chemotherapeutic agents, including cyclophosphamide, methotrexate, chlorambucil, and 2-
chlorodeoxyadenosine. UVA-1 or PUVA phototherapy, Grenz ray, and total skin electron-beam therapy. 
 
  
Intravenous immunoglobulin 
2 g/kg/month for at least 
6 months 
Thalidomide: 100–400 mg/day 
Lenalidomide: 25 mg/day for 3 weeks/month 
Systemic glucocorticoids 
Prednisone: 0.5–1.0 mg/kg/day, 
Dexamethasone: 40 mg/day for 4 days/week 
Melphalan: 1–4 mg/day 
Bortezomib + dexamethasone 
Consider autologous stem 
cell transplantation 
Consider other therapies* Dermato-neuro syndrome 
Progressive disease or 
insufficient response 
Severe of refractory disease 
Insufficient response 
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III  Systemic sclerosis 
 
Introduction 
The diagnosis and treatment of systemic scleroderma/systemic sclerosis (SSc) is challenging 
due to the heterogeneity of disease manifestations and disease course. Diagnosis and care 
should, at least in part, be in the hands of specialists who have daily exposure to the disease and 
have access to modern diagnostic procedures (e.g. high-resolution computed tomography [HR-
CT], magnetic resonance imaging (MRI), body plethysmography, echocardiography, 
gastroscopy, spirometry, and nailfold capillaroscopy) and to a laboratory with expertise in 
autoimmune serology. In order to provide optimal care, cooperation with different 
subspecialties (e.g. rheumatology, dermatology, gastroenterology, pulmonary medicine, 
cardiology, nephrology) is necessary due to the nature of the disease, which affects several 
organ systems.  
 
Systematic baseline and longitudinal assessments to define the complications are mandatory. 
Multidisciplinary care for patients with early progressive disease should be provided in a setting 
where the outpatient facilities also have access to hospital beds in order to ensure timely and 
appropriate treatment for patients presenting with exacerbation of their disease. In these 
specialized facilities, access to physical therapy should be available.  
 
In 2009, for the first time evidence-based recommendations for the treatment of SSc were 
published by the European League against Rheumatism Scleroderma Trials and Research 
(EUSTAR) study group,1 where many of the recommendations given below are described in 
more detail. An updated form of the EUSTAR treatment recommendations is in preparation and 
is due to be published in 2016. In addition, for a more detailed description, the reader is referred 
to the “Consensus best practice recommendations for scleroderma” developed by UK 
Scleroderma Study Group.2  
 
The present guideline has been prepared bearing in mind that healthcare systems differ 
considerably between countries in Europe. The recommendations, as presented here, may be 
influenced, among others, by hospitalization rules, the availability of outpatient facilities, and 
financial reimbursement of specific procedures and therapies. 
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Clinical manifestation and classification 
SSc is a heterogeneous, chronic autoimmune disorder, leading to fibrosis of the skin and many 
internal organs.3 In 1980, the American College of Rheumatology published preliminary 
criteria for the classification of patients with established disease.4 A subclassification, 
developed by LeRoy et al., has been the most widely used classification system in clinical 
practice,5 and forms the basis for many registries worldwide (Table 1). In this classification, 
diffuse cutaneous SSc (dcSSc) is defined as a progressive form with an early onset of Raynaud’s 
phenomenon, usually within 1 year of the onset of skin changes. This subset is characterized 
by rapid involvement of trunk, face, proximal and distal extremities. Very frequently, anti-
topoisomerase-1 antibodies (anti-topo-1, anti-Scl-70) are present.6–8 
 
<TABLE 1> 
 
Limited cutaneous SSc (lcSSc) is defined by skin affection of the extremities distal to the elbow 
and knee joints. These patients often (50–70%) have anti-centromere antibodies (ACA).6–8 It 
has been widely accepted that the so called “CREST syndrome” and “systemic sclerosis sine 
scleroderma” can be seen as part of the disease spectrum of the limited cutaneous form of SSc.9 
 
In 2013, the American College of Rheumatology (ACR) and the European League Against 
Rheumatism (EULAR) published new classification criteria (Table 2).10 The classification 
incorporates diagnostic measures, such as anti-nuclear antibodies and capillaroscopy, which 
have not been included before. However, when applying these new classification criteria it 
should be kept in mind that they were developed primarily for clinical research purposes and 
cannot be applied to patients without skin involvement of the hands or to patients with 
scleroderma-like disorders.  
 
For patients with very early disease (also referred to as very early/early SSc, pre-SSc, or 
undifferentiated connective tissue disease), there are no generally accepted criteria.11 In these 
cases, it has to be considered, that, for instance, only two-thirds of patients with Raynaud’s 
phenomenon, nailfold capillaroscopic changes, and/or SSc-specific antibodies (ACA, anti-
topo-1) will develop definite SSc after 5 years.12 Nevertheless, almost 80% of these patients 
develop SSc in the long term. In addition, patients without a scleroderma pattern on 
capillaroscopy nor presence of SSc-specific antibodies do not develop SSc (1.8% during long-
term follow-up).12 Subsequently, capillaroscopy and SSc-specific antibodies seem to be good 
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prognostic predictors for the disease. Therefore, it is recommended that patients with suspected 
early SSc are referred to centers that are experienced in SSc diagnosis and care. 
 
Diagnostic procedures 
Antinuclear antibodies 
Autoantibodies targeting characteristic nuclear antigens are one of the hallmarks of SSc. The 
frequency of detection of antinuclear antibodies (ANA) in SSc patients in a recent study 
approached 95%,8 which corresponds well with ANA frequencies of between 85% and 99% 
reported in the literature. In this study, 86.6% of the ANA-positive patients had SSc-specific 
antibodies, 96.4% of which were detecting five antigens (i.e. centromere, topoisomerase-1, 
RNA polymerase III, PM/Scl, U1-RNP) (Table 3). It is generally well accepted that the SSc-
specific antibodies described above are largely mutually exclusive. Coincidences in individual 
patients do occur but are rare. 
 
For a more detailed description of autoantibodies linked to overlap syndromes, please see 
section V (Systemic sclerosis overlap syndromes).  
 
<TABLE 3> 
 
Capillaroscopy 
Capillaroscopy (e.g. videocapillaroscope, stereomicroscope, or dermatoscope) is a well-
established, non-invasive technique for the identification of changes in the nailfold capillary 
that differentiate primary Raynaud’s phenomenon from SSc.  
 
For a detailed review the reader is referred to the article by Cutolo et al.13  
 
Organ involvement and diagnostic work-up 
Raynaud’s phenomenon 
Raynaud’s phenomenon is characterized by a vasospasm resulting in blanching, cyanosis, and 
then reactive hyperemia (triphasic). Raynaud’s phenomenon is present in more than 90% of 
patients. It typically affects the hands, less commonly the feet, but may also involve the tongue, 
ears, and nose. Cold exposure is the usual trigger, but emotional stress may evoke the same 
symptoms. 
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Primary Raynaud’s phenomenon is mainly caused by functional disturbances, whereas in 
secondary Raynaud’s phenomenon in the context of SSc, there is also involvement of structural 
alterations in digitate arteries. These combined changes are considered to be major causes for 
the formation of ulcers. To distinguish primary from secondary Raynaud’s phenomenon, 
nailfold capillaroscopy and the analysis of autoantibodies are required. Additional laboratory 
and radiologic examinations may become necessary in order to exclude other factors that may 
contribute to the symptoms of Raynaud’s phenomenon.14 
 
Skin fibrosis 
At the onset of the disease, particularly in the diffuse form, patients tend to have swollen fingers 
and hands over extended periods of time, so called “puffy hands.” Sclerotic changes follow 
later on, finally leading to dermatogenic contractures and sclerodactyly. Perioral plication and 
microstomia are typical features of the face, as is a mask-like stiffness. 
 
The best and validated tool to measure the progress of the skin sclerosis is the modified Rodnan 
Skin Score (mRSS). At 17 different anatomical areas, the skin score is evaluated by manual 
palpation. The skin score is 0 for uninvolved skin, 1 for mild thickening, 2 for moderate 
thickening, and 3 for severe thickening. Subsequently, the sum will be used as the total skin 
score. The mRSS is feasible, reliable, and has been validated for initial and follow-up skin 
evaluation. The administration of this simple method requires some experience, and a careful 
teaching process is warranted.15  
 
Skin involvement and its rate of progression are thought to reflect the severity of internal organ 
involvement. However, in later disease stages, internal organ involvement may progress while 
skin fibrosis of the trunk and proximal extremities will diminish.  
 
Fibrosis may be accompanied by additional symptoms such as hair loss, diminished sweating, 
hyperpigmentation, depigmentation, or severe pruritus. 
 
Digital ulceration 
Among patients with SSc, 15–25% have active digital ulceration (DU) and 35% have or have 
had DUs in the past, although this number varies considerably between centers and studies.16–
19 Analysis of registry data indicates that the extent of skin sclerosis, male sex, presence of 
pulmonary arterial hypertention, involvement of the esophagus, presence of anti-topo-1 (but 
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not anti-centromere) antibodies, early age at onset of Raynaud’s phenomenon, and elevated 
erythrocyte sedimentation rate could be independent risk factors.16,18 History of DU when 
patients first present has been shown to predict the occurrence of DUs at follow-up, and is 
associated with cardiovascular worsening and decreased survival.20 
 
Ulcers that occur on the fingertip are thought to be exclusively due to ischemia, whereas ulcers 
over the extensor surfaces of the proximal and distal interphalangeal joints have a mixed 
etiology. They are usually due to a combination of poor perfusion, stretched fibrotic skin, and 
trauma. DUs are complicated by secondary infection, osteomyelitis, gangrene, and amputation. 
Acro-osteolysis may further complicate wound healing. Recurring ulcers lead to chronic use of 
pain relievers and antibiotics, and eventually to hospitalization either for treatment of active 
DUs or for surgery (amputation).21  
 
Contributory causes, such as coexisting large vessel disease, should be excluded. In addition, 
differential diagnoses, such as vasculitis, thrombangitis, or arteriosclerotic vascular disease, 
should be ruled out. Calcinosis cutis should be distinguished from superficial ulceration, but is 
a possible risk factor for DU. 
 
Calcinosis cutis 
Calcinosis cutis is marked by subcutaneous calcium carbonate deposits, which appear in all 
subtypes of SSc and most frequently on the acral parts of the body. They may induce superficial 
erosions and cause intense pain for the patient. Calcinosis cutis is an important differential 
diagnosis to DUs and can be excluded via X-ray of the affected body parts. 
 
Musculoskeletal system 
Arthralgia and musculoskeletal pain are among the most frequent complaints in SSc and may 
lead to secondary fibromyalgia. Tendon friction rubs are a typical sign of an inflammatory, 
progressive form of the disease. Muscle weakness and a varying increase in serum creatine 
kinase levels are quite common and can indicate the presence of an SSc-myositis overlap 
syndrome (i.e. Scl syndrome, anti-synthetase syndrome, mixed connective tissue disease). In 
these cases, magnetic resonance imaging and a muscle biopsy to determine the type of myositis 
should be considered. 
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Inflammatory arthritis can occur in up to 10% of patients and raises the suspicion of the 
presence of an SSc overlap syndrome (SSc-rheumatoid arthritis). In these cases, rheumatoid 
factors and anti-cyclic citrullinated peptide (CCP) antibodies (ACPA) (Table 3) should be 
determined and a rheumatologic work-up initiated. A more detailed description of the diagnosis 
and treatment can be found in section V (Systemic sclerosis overlap syndromes). 
 
Pulmonary involvement 
Interstitial lung disease 
Interstitial lung disease (ILD) affects up to 65% of SSc patients to varying degrees. The typical 
presentation is a predominantly bibasilar pattern. While some patients develop a rapid decline 
of forced vital capacity (FVC) within the first 3 years, others may remain remarkably stable or 
may even experience improvement.22 In early disease, inflammatory alveolitis may precede 
and/or accompany interstitial fibrosis, leading to loss of pulmonary function as evidenced by 
decreased diffusing capacity of the lungs for carbon monoxide (DLCO) and decreased FVC in 
more severe cases. Most often the ILD corresponds to a non-specific interstitial pneumonitis.  
 
The majority of patients will present with symptoms such as dyspnea, a dry cough, and reduced 
exercise tolerance. Chest X-ray can be useful but is a relatively insensitive method for the 
detection of ILD. Chest HR-CT has a markedly higher diagnostic sensitivity and is the 
recommended diagnostic tool to determine the extent and distribution of ILD. The sensitivity 
of HR-CT is superior when compared with lung function testing (LFT).23 LFT should include 
spirometry, body plethysmography, and DLCO (corrected for hemoglobin). LFT should be 
performed every 6 months, or more frequently if the patient is developing a loss in FVC and/or 
a decrease in transfer factor (DLCO).  
 
Pulmonary hypertension 
Pulmonary arterial hypertension (PAH) occurs in about 15% of patients, and develops 
particularly in patients with long disease duration and anti-centromere antibodies. PAH is 
associated with significant mortality and is among the most common causes of death in SSc.24 
All SSc patients should be evaluated for possible PAH in line with current recommendations, 
and referred for specialist management. Annual screening on symptoms (unexplained or 
progressive dyspnea, syncope, signs of right heart failure) and by echocardiography are strongly 
recommended in all SSc patients,1 and are part of the current recommendations of cardiologic 
and pulmonary societies (see 2015 Guidelines of the European Society of Cardiology25). 
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Gastrointestinal involvement 
The gastrointestinal tract is frequently involved, with 80% of patients having esophageal 
involvement and 40–70% having involvement of the stomach, small intestine, and large 
intestine.7,26 In longstanding disease (i.e. >10 years), upper gastrointestinal involvement occurs 
in nearly all patients. The most common symptoms are heartburn, esophageal dysfunction in 
the upper gastrointestinal tract, diarrhea due to bacterial overgrowth, and fecal incontinence in 
the distal tract. Barrett’s esophagus is a late sequel of reflux disease and requires surveillance 
according to the respective guidelines.27  
 
Rarely, telangiectasias may also be present on the mucosa, representing a potential source of 
occult intestinal bleeding. The standard diagnostic procedure is endoscopy.  
 
Cardiac involvement 
The nature and severity of cardiac disease depends on the extent of myocardial fibrosis, and on 
the extent to which concurrent fibrosis of the lung and thickening and fibrosis of the small 
pulmonary arteries place an additional burden on the circulation. Myocarditis and pericarditis 
can be observed in a subset of patients and may lead to diagnostic uncertainty. Risk factors for 
cardiac involvement are diffuse disease, particularly with rapid progression, and signs of 
inflammation such as tendon friction rubs. Patchy myocardial fibrosis contributes to diastolic 
dysfunction and to a diminished left ventricular ejection fraction.  
 
Arrhythmias are quite common in SSc. In patients with the diffuse form of SSc, severe forms 
of arrhythmias are considered an important source of mortality.28 As regular electrocardiogram 
is relatively insensitive, there should be a low threshold to use Holter monitoring. 
 
Renal involvement 
Acute renal crisis is a serious and potentially fatal SSc complication. It occurs most likely in 
patients with the progressive, diffuse form with a disease duration of less than 4 years. The 
presence of anti-RNA polymerase III antibodies is considered a particular risk factor and is 
detected in about one third of cases.29 Thus, regular control of blood pressure (at least twice 
weekly/home monitoring) is recommended to detect acute renal involvement early on. 
Glucocorticoids in higher doses exceeding 15 mg prednisone equivalents should be avoided 
due to their long-term side-effects and association with renal crisis.29 
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In a small subset of patients, normotensive acute renal crisis will develop. In these cases, 
patients often present with signs of thrombotic microangiopathy. Chronic renal involvement in 
SSc is associated with a slowly progressive obliterative vasculopathy. Urinary protein excretion 
has been determined in several studies as a major independent risk factor for mortality.30 
Therefore, urinary protein excretion should be determined at least annually. 
 
General recommendation for a regular diagnostic work-up in patients with SSc 
After an initial baseline assessment (Table 4), at least annual, life-long, follow-up of patients is 
recommended due to the chronic nature of the disease. In patients with progressive disease, 
corresponding with disease activity, patients should be followed more frequently. The annual 
work-up should include a thorough clinical investigation including mRSS and the following 
diagnostic measures: lung function test with plethysmography including DLCO, blood 
pressure, electrocardiography, echocardiography, Erythrocyte sedimentation rate/C-reactive 
protein, complete blood count, clinical chemistry (liver function, creatinine, urea) and urinary 
protein.  
 
Particularly in patients with an increased risk for renal crisis (progressive diffuse disease, anti-
RNA polymerase III antibodies), frequent blood pressure measurements are recommended 
(preferably home monitoring) (Table 5). 
 
<TABLE 4> 
<TABLE 5> 
 
Treatment 
Therapy for skin involvement 
Treatment of Raynaud’s phenomenon 
Avoidance of cold exposure and the constant protection against cold is paramount. Heated 
gloves, shoes, and pockets are usual measures. Furthermore, paraffin baths, heated seed pillows, 
therapy balls, and physical therapy are recommended.31 Smoking should be stopped. Beta-
blocker treatment should be substituted, if feasible. 
 
These lifestyle measures should be supported by pharmacologic therapy (Fig. 1). First-line 
therapy consists of calcium antagonists such as nifedipine or amlodipine. Large meta-analyses 
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have revealed that calcium antagonists reduce the severity and frequency of Raynaud’s attacks. 
The dosage should be increased carefully. Recent controlled studies indicated that PDE-5 
inhibitors (i.e. sildenafil, vardenafil) may also be effective in the treatment of Raynaud’s 
phenomenon, by reducing the severity and frequency of attacks.32–34 However, these drugs have 
not been licensed for this indication. Selective serotonin reuptake inhibitors, such as fluoxetine, 
have shown benefit in some patients,35 and angiotensin-converting enzyme (ACE) inhibitors or 
angiotensin-receptor antagonists may also be considered.36 
 
<FIGURE 1> 
 
An improvement of severe Raynaud’s phenomenon has been demonstrated following 
intravenously administered iloprost.37,38 A dosage of 0.5–2 ng/kg/min for 3–6 hours on at least 
five consecutive days at monthly intervals is generally recommended.1,39 The most frequent 
side-effects are headaches, low blood pressure, and cutaneous flushing. To minimize these side-
effects, a slow daily increase of the dosage, depending on the individual patient’s condition, is 
necessary.39  
 
Digital (palmar) sympathectomy (with or without botulinum toxin injection) may be considered 
in severe and/or refractory cases. 
 
Treatment of digital ulceration 
Avoidance of cold exposure and cessation of smoking are accompanying measures. Beta-
blocker treatment should be substituted, if feasible. A modified algorithm as published by 
Riemekasten et al.40 is shown in Fig. 2.  
 
Infections, especially those that affect deep adjacent structures, should be treated with 
antibiotics in order to prevent osteomyelitis and avoid amputation.41 If possible, the antibiotic 
therapy should be combined with a vasodilatory therapy to improve perfusion of the involved 
area. Sufficient analgesic therapy is recommended to improve quality of life and to reduce pain-
induced vasoconstriction. Adequate wound care and regular clinical inspection are mandatory, 
in order to prevent infections, gangrene or necrosis.41 In the case of dry, superficial ulcers, non-
occlusive wound care is recommended. The use of a protective wound dressing (i.e. alginate) 
is advised when deep ulcers are present in order to protect the wound from sources of infection 
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and to support granulation. Wound care includes a thorough cleaning and disinfection of the 
wound with sodium chloride, antiseptics or wound cleansing solutions. 
 
Two randomized controlled trials demonstrated that intravenous iloprost is efficacious in 
healing digital ulcers in SSc. It should be administered at a dosage of 0.5–2 ng/kg per minute 
for 3–6 hours for at least five consecutive days.1,39 The recommended treatment duration varies 
between 3 and 14 days, and is in part influenced by restrictions in the respective national 
healthcare system.39  
 
A recent meta-analysis of several randomized controlled trials indicated that PDE-5 inhibitors 
improve healing of digital ulcers.42 Therefore, PDE-5 inhibitors can be considered for the 
treatment of active digital ulcers. 
 
Bosentan is a non-selective endothelin receptor antagonist that demonstrated efficacy in the 
prevention of digital ulcers in two randomized and controlled studies (RAPIDS-1 and -2) in 
SSc patients.43–45 A significant reduction in the number of new ulcers was revealed, particularly 
in patients with multiple ulcers. Side-effects consist of possible liver toxicity, teratogenicity, 
and reduced effectiveness of oral contraceptive pills through interference with the cytochrome 
P450 system.1,42 Bosentan does not affect healing of active DUs. 
 
Digital (palmar) sympathectomy (with or without botulinum toxin injection) may be considered 
in severe and/or refractory cases.36 
 
Treatment of skin fibrosis  
Therapy for skin sclerosis should be guided by the phase of the fibrotic process (early phase vs. 
late phase), the disease activity, and the progression of the fibrosis. General measures include 
skin protection from cold and trauma, skin care with moisturising creams, lymph drainage, and 
active physiotherapy for the prevention of contractures. These general measures may suffice in 
mild, non-progressing forms of fibrosis. 
 
In the early phase with limited skin involvement and LS, UVA1 or photochemotherapy (PUVA) 
should be considered. Similarly to the successful treatment of LS with UVA modalities, a 
number of uncontrolled studies have indicated a beneficial effect on fibrosis in SSc.46–48 
However, controlled studies are still lacking. Pruritus often occurs in fibrotic skin, and may 
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respond to standard therapy and phototherapy. For further details, the reader is referred to Fig. 
1 in the LS section, However, longer treatment durations may be needed.  
 
Photopheresis (extracorporeal photochemotherapy) has shown promise in several controlled 
studies.49,50 It can be used as second-line or adjuvant therapy. It is recommended that it should 
be applied in early progressive disease, preferably of less than 2 years’ duration. For more 
details, the reader is referred to the 2014 EDF guideline.51 
 
The systemic use of glucocorticoids, which is considered a standard therapy for most 
autoimmune diseases, plays no role in the therapy of fibrosis in patients with SSc.1 More 
importantly, it is well known that glucocorticoids in a dose of >15 mg are associated with a 
higher incidence of renal crisis.29 
 
The best data for systemic therapy of progressive skin fibrosis are available for methotrexate. 
In two randomized, controlled studies it was shown that methotrexate decreased skin fibrosis 
in early diffuse SSc. Positive effects on other organs such as the lung could not be shown.52,53 
A dosage of 10–15 mg per week for 6–12 months is generally recommended. Higher dosages 
may be considered. The use of mycophenolate mofetil (MMF) is recommended by the 
EUSTAR study group as second-line therapy following methotrexate.1,54 The recommended 
standard dosage varies at about 1–2 g per day for at least 12 months.1,54  
 
An improvement of skin sclerosis was demonstrated for cyclophosphamide in the scleroderma 
lung study.1,55 The use of cyclophosphamide is recommended after failure of methotrexate and 
MMF due to high rates of side-effects.54 As renewed deterioration of mRSS and lung 
involvement were observed during follow-up in the scleroderma lung study, a continuation of 
immunosuppression with MMF or azathioprine after cyclophosphamide therapy is 
recommended by some experts. An algorithm for the treatment of SSc skin fibrosis is shown in 
Fig. 3. 
 
Treatment of calcinosis cutis 
Various therapeutic strategies have been investigated, but there is currently no evidence of an 
effective therapy for calcinosis cutis. Ectopic calcifications or calcinosis that compromise blood 
circulation or cause symptoms may be removed surgically or by the use of carbon dioxide laser. 
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Surgical excision seems to be the best option after failure of conservative treatment attempts. 
However, surgery should only be performed in cases of urgent medical indication.56–58 
 
Treatment of telangiectasias 
Telangiectasia may appear in the face, the hands (even on the palms), and the mucosa of patients 
with SSc.59,60 Laser (i.e. potassium titanyl phosphate or flashlamp pulsed dye laser) or intense 
pulsed light therapy is the treatment of choice to remove telangiectasias.59,61 Cosmetics are often 
used to cover the affected area. 
 
Therapy for musculoskeletal involvement 
For detailed treatment recommendations, the reader is referred to Section V (Systemic sclerosis 
overlap syndromes).  
 
Therapy for pulmonary involvement 
Treatment of lung fibrosis 
ILD in many patients is relatively mild and has a low rate of progression. However, particulary 
in patients with progressive diffuse disease, a severe reduction in FVC can ensue and the 
progressive lung fibrosis is recognized as a major cause of mortality.22 It is therefore crucial to 
identify patients with risk for ILD and to identify patients with a significant progression as 
measured by a reduction of FVC (>5% in 6 months or >10% in 1 year) or DLCO (>15% in 
1 year). Patients with ILD should be considered for early treatment, when the disease is active 
and the damage is not yet irreversible. Another component of therapy should be adequate 
treatment of reflux disease, as this may prevent progression of ILD.62  
 
The best available data exist for cyclophosphamide, which showed a modest, statistically 
significant benefit in a randomized, controlled, double-blind trial on both lung and skin 
fibrosis.55 As the follow-up data of this trial indicated a renewed progression of fibrosis, several 
groups recommend the prolongation of immunosuppression after 6 or 12 pulses of 
cyclophosphamide by the use of azathioprine or MMF.54 
 
Two randomized controlled trials and a number of uncontrolled studies have shown that 
hematopoietic stem cell transplantation improves lung function and skin fibrosis compared with 
standard immunosuppressive treatment.63,64 Transplantation can result in rapid (over months) 
and sustained improvement of mRSS and FVC. However, in the first year, a significantly 
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increased mortality was observed in the transplantation arm.63 Careful selection of SSc patients 
for transplantation is mandatory. 
 
Treatment of pulmonary arterial hypertension 
Drugs targeting different aspects of vascular pathology have become available in recent years 
and have dramatically changed therapy of PAH. The diagnosis and therapy of PAH belong in 
the hands of an experienced cardiologist/pulmonologist with special expertise in right heart 
disease. The primary task of the dermatologist taking care of an SSc patient will be to initiate 
regular (i.e. at least annual) echocardiography, and to have a high clinical suspicion for this 
complication (see 2015 guidelines of the European Society of Cardiology25).  
 
Therapy for gastrointestinal involvement 
Standard treatment for gastrointestinal reflux disease and the prevention of esophageal ulcers 
and strictures is proton pump inhibitors (i.e. pantoprazole 40 mg/day). The majority of patients 
require maintenance therapy. Second-line options are H2-blockers and antacids, in addition to 
appropriate lifestyle changes.1,65  
 
Telangiectasias may occur and cause gastrointestinal bleeding (i.e. gastric antral venous 
ectasia), which should be treated by endoscopic coagulation.  
 
Prokinetic dopamine agonists may be used for dysphagia and reflux (e.g. metoclopramide, 
octreotide).66 Bacterial overgrowth and fungal infections (e.g. candida esophagitis) can be 
managed by intermittent antimicrobial therapy and antimycotics.67 Anti-diarrheal agents (e.g. 
loperamide) or laxatives may be used for the symptomatic management of diarrhea or 
constipation that often alternate as clinical problems. Parenteral nutrition should be considered 
for patients with severe weight loss refractory to enteral supplementation. For a more detailed 
overview, the reader is referred to the consensus best practice pathway of the UK scleroderma 
study group.27 
 
Therapy for renal involvement 
Acute renal crisis was the major cause of death before the advent of ACE-inhibitor therapy. 
Prompt recognition of scleroderma renal crisis and initiation of therapy with an ACE inhibitor 
offers the best opportunity for a good outcome. Other anti-hypertensive agents may be 
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considered for managing refractory hypertension in conjunction with ACE in scleroderma renal 
crisis.  
 
General recommendations for disease management 
In order to tailor treatment to the individual patient, it is important to determine disease subset, 
organ involvement, and disease activity. In recent years, the organ-based approach has brought 
forward significant pharmacologic advancements, changing remarkably the prognosis and life 
quality of patient subgroups (Table 6).  
 
Multidisciplinary care of SSc patients should aim beyond the treatment of classic organ 
involvement. Quality of life is increasingly acknowledged in clinical studies and has to be 
addressed. The psychosocial well-being of SSc patients is often severely affected by the 
impression of disfigurement (e.g. from telangiectasias, microstomia, contractures), and patients 
should be appropriately counseled. This also applies to the treatment of chronic pain and 
depression/anxiety. It has been shown that pain is an important indicator of sexual dysfunction 
among women with SSc.68 Similarly, erectile dysfunction in male patients is markedly 
underdiagnosed and undertreated.69 Involvement of the masticatory organ may be significant 
and lead to remarkable deterioration of life quality. Sicca syndrome, gingivitis, tooth decay, 
and osteolysis/necrosis all contribute to a deterioration of oral health-related quality of life. 
Adjunctive therapy such as physiotherapy and respiratory therapy should be considered early 
in the course of organ involvement. Small open controlled trials suggest that manual lymphatic 
drainage may improve hand function in SSc.  
 
Modern comprehensive disease management in SSc patients should be directed at the 
underlying disease process and the resulting organ complications, and should also consider the 
associated physical and psychological consequences. 
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Table 1 Subclassification of LeRoy et al. (1988)5 
Limited form Diffuse form 
• Acral sclerosis 
• Skin involvement of the extremities distal to the 
elbow and knee joints 
• Possible involvement of the face 
• Long duration of Raynaud’s phenomenon 
• Late pulmonary arterial hypertension 
• Often anti-centromere positive 
• Progressive systemic sclerosis 
• Rapid involvement of the trunk, face, and 
extremities 
• Lung fibrosis 
• Early onset of Raynaud’s phenomenon (within 
1 year of skin changes) 
• Often anti-topoisomerase-1 positive 
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Table 2 American College of Rheumatology/European League against Rheumatism 2013 
criteria for classification of systemic sclerosis 
Item Sub-item(s) Weight/score* 
Skin thickening of the fingers of both hands 
extending proximal to the metacarpophalangeal 
joints (sufficient criterion) 
– 9 
Skin thickening of the fingers (only count the 
higher score) 
Puffy fingers 2 
Sclerodactyly of the fingers (distal to the 
metacarpophalangeal joints but proximal 
to the proximal interphalangeal joints) 
4 
Fingertip lesions (only count the higher score) Digital tip ulcers 2 
Fingertip pitting scars 3 
Telangiectasia – 2 
Abnormal nailfold capillaries – 2 
Pulmonary arterial hypertension and/or 
interstitial lung disease (maximum score is 2) 
Pulmonary arterial hypertension 2 
Interstitial lung disease 2 
Raynaud's phenomenon – 3 
SSc-related autoantibodies (anti-centromere, 
anti-topoisomerase-1 [anti-topo-1, anti-Scl-70], 
anti-RNA polymerase III) (maximum score is 3) 
Anti-centromere 3 
Anti-topoisomerase-1  
Anti-RNA polymerase III  
SSC, systemic sclerosis. 
*Score ≥9 is classified as SSc. 
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Table 3 Autoantibodies in systemic sclerosis 
Antibodies Organ involvement 
SSc-specific autoantibodies  
Centromere Pulmonary arterial hypertension 
Topoisomerase-1 (Scl-70) Digital ulcerations, interstitial lung disease, skin fibrosis 
RNA polymerase III Renal crisis, skin fibrosis, paraneoplasia 
PM/Scl Myositis, interstitial lung disease 
U1-RNP Joints 
SSc-associated antibodies  
Ro, La Parotis (Sjögren syndrome) 
CCP Arthritis 
Rheumatoid factor Arthritis 
Mitochondrial (M2) Liver (primary biliary cirrhosis) 
CCP, cyclic citrullinated peptide. 
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Table 4 Organ oriented baseline work-up 
 
General 
• History and physical examination 
• ESR/CRP 
• Blood count 
• Clinical chemistry 
• Autoantibody testing 
 
Skin 
• Modified Rodnan Skin Score  
 
Musculoskeletal 
• Clinical exam 
• Creatine kinase 
• Anti-CCP 
• Rheumatoid factor 
 
Gastrointestinal 
• Upper gastrointestinal endoscopy 
 
Lung 
• High-resolution computed tomography 
• Lung function (FVC, DLCOc/SB) 
 
Heart 
• Electrocardiogram 
• Echocardiography 
 
Kidney 
• Blood pressure (weekly self-monitoring in high-risk patients [anti-RNA polymerase III+]) 
• Creatinine 
• Urinary protein 
 
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; CCP, cyclic citrullinated peptide; FVC, forced vital 
capacity; DLCOc/SB, diffusing capacity of the lungs for carbon monoxide per single breath. 
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Table 5 Organ oriented recommended annual work-up 
 
General 
• History and physical examination 
• ESR/CRP 
• Blood count 
• Clinical chemistry 
 
Skin 
• Modified Rodnan Skin Score 
 
Lung 
• Lung function (FVC, DLCOc/SB) 
 
Heart 
• Electrocardiogram 
• Echocardiography  
 
Kidney 
• Blood pressure (weekly self-monitoring in high-risk patients [RNA-polymerase +]) 
• Creatinine 
• Urinary protein  
 
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; FVC, forced vital capacity; DLCOc/SB, diffusing 
capacity of the lungs for carbon monoxide per single breath. 
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Table 6 Therapy of internal organ involvement 
 
Gastrointestinal involvement 
• Proton pump inhibitor, H2 blockers, antacids 
• Prokinetics (metoclopramide, octreotide)  
• Antibiotics (bacterial overgrowth) 
• Laxatives, loperamide 
• Parenteral nutrition 
 
Pulmonary arterial hypertention 
• Prostanoids 
• Endothelin receptor antagonist, PDE-5 inhibitor, Riociguat 
 
Lung (interstitial lung disease) 
• Cyclophosphamide 
• Hematopoietic stem cell transplantation 
 
Kidney 
• Angiotensin-converting enzyme inhibitor 
 
PDE, phosphodiesterase.  
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Figure 1 Flow chart for management of Raynaud’s phenomenon. 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Herrick et al., 2012.14 
PDE, phosphodiesterase; SSRI, selective serotonin reuptake inhibitor; ATRA, angiotensin receptor antagonist; 
ASA, acetylsalicylic acid. 
 
  
General measures 
Lifestyle changes 
Supportive care 
Calcium-channel blockers 
 ASA, clopidogrel? PDE-5 inhibitor, SSRI, ATRA IV iloprost 
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Figure 2 Flow chart for management of digital ulcerations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Riemekasten et al., 2012.40 
PDE, phosphodiesterase. 
 
 
  
Preventive measures 
Underlying disease? 
Macrovascular disease? 
Digital ulceration Wound management 
Iloprost 5 days 
Repeat iloprost Bosentan PDE-5 inhibitor 
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Figure 3 Flow chart for therapy of skin fibrosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MMF, mycophenolate mofetil. 
 
Lifestyle modification 
Skin care 
Physiotherapy 
Inflammatory, progressive disease Mild disease 
Methotrexate, MMF, cyclophosphamide  phototherapy 
Stable disease or regression 
Consider stem cell transplantation 
Phototherapy 
78 
References 
1. Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, et al. EULAR 
recommendations for the treatment of systemic sclerosis: a report from the EULAR 
Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620–628. 
2. UK Scleroderma Study group. Consensus best practice recommendations for scleroderma. 
Available at: http://www.scleroderma-royalfree.org.uk/UKSSG.html (last accessed 28 
February 2016) 
3. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360: 1989–
2003. 
4. Masi AT and Subcommittee for Scleroderma Criteria of the American Rheumatism 
Association Diagnostic and Therapeutic Criteria Committee (1980). Preliminary criteria 
for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–
590. 
5. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, 
subsets and pathogenesis. J Rheumatol 1988; 15: 202–205. 
6. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and 
disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 
2003; 48: 2246–2255. 
7. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations 
in systemic sclerosis – a report from the EULAR Scleroderma Trials and Research 
(EUSTAR) group data base. Ann Rheum Dis 2007; 66: 754–763. 
8. Mierau R, Moinzadeh P, Riemekasten G, et al Frequency of disease-associated and other 
nuclear autoantibodies in patients of the German network for systemic scleroderma: 
correlation with characteristic clinical features. Arthritis Res Ther 2011; 13: R172. 
9. Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: 
demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis 
Rheum 2000; 43: 444–451. 
10. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 
classification criteria for systemic sclerosis: an American College of Rheumatology/ 
European League against Rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 
1747–1755. 
11. Valentini G. Undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) 
(so far referred to as very early/early SSc or pre-SSc). Autoimmun Rev 2015; 14: 210–213.  
79 
12. Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are 
independent predictive factors for the progression of Raynaud’s phenomenon to systemic 
sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed 
criteria for early systemic sclerosis. Arthritis Rheum 2008; 58: 3902–3912. 
13. Cutolo M, Sulli A, Smith V. How to perform and interpret capillaroscopy. Best Pract Res 
Clin Rheumatol 2013; 27: 237–248. 
14. Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev 
Rheumatol 2012; 8: 469–479 
15. Czirják L, Foeldvari I, Müller-Ladner U. Skin involvement in systemic sclerosis. 
Rheumatology 2008; 47(Suppl 5): v44–45. 
16. Khimdas S, Harding S, Bonner A, et al. Associations with digital ulcers in a large cohort 
of systemic sclerosis: results from the Canadian Scleroderma Research Group registry. 
Arthritis Care Res 2011; 63:142–149. 
17. Mouthon L, Mestre-Stanislas C, Bérezné A, et al. Impact of digital ulcers on disability and 
health-related quality of life in systemic sclerosis. Ann Rheum Dis 2010; 69: 214–217 
18. Sunderkoetter, Herrgott I, Brückner C, et al. Comparison of patients with and without 
digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 2009; 
160: 835–843. 
19. Ennis H, Vail A, Wragg E, et al. A prospective study of systemic sclerosis-related digital 
ulcers: prevalence, location, and functional impact. Scand J Rheumatol 2013; 42: 483–486 
20. Mihai C, Landewé R, van der Haijde D, et al. Digital ulcers predict a worse disease course 
in patients with systemic sclerosis. Ann Rheum Dis 2015; doi: 10.1136/annrheumdis-2014-
205897. 
21. Hachulla E, Clerson P, Launay D, et al. Natural history of ischemic digital ulcers in 
systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007; 34: 
2423–2430. 
22. Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. 
Eur Respir Rev 2013; 22: 6–19. 
23. Hoffmann-Vold AM, Aaløkken TM, Lund MB, et al. Predictive value of serial high-
resolution computed tomography analyses and concurrent lung function tests in systemic 
sclerosis. Arthritis Rheumatol 2015; 67: 2205–2212. 
24. Steen VD, Medsger TA Jr. Changes in causes of death in systemic sclerosis, 1972–2002. 
Ann Rheum Dis 2007; 66: 940–944. 
80 
25. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the 
European Society of Cardiology (ESC) and the European Respiratory Society (ERS). 2015 
ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur 
Respir J 2015; 46: 1855–1856 
26. Hunzelmann N, Genth E, Krieg T, et al. The registry of the German Network for Systemic 
Scleroderma: frequency of disease subsets and patterns of organ involvement. 
Rheumatology 2008; 47: 1185–1192. 
27. Hansi N, Thoua N, Carulli M, et al. Consensus Best Practice pathway of the UK 
Scleroderma Study Group: gastrointestinal manifestations of systemic sclerosis. Clin Exp 
Rheumatol 2014; 32(Suppl 86): S-214–221. 
28. Vacca A, Meune C, Gordon J, et al. Scleroderma Clinical Trial Consortium Cardiac 
Subcommittee. Cardiac arrhythmias and conduction defects in systemic sclerosis. 
Rheumatology 2014; 53: 1172–1177.  
29. Mouthon L, Bussone G, Berezné A, Noël LH, Guillevin L. Scleroderma renal crisis. J 
Rheumatol 2014; 41: 1040–1048. 
30. Fransen J, Popa-Diaconu D, Hesselstrand R, et al. Clinical prediction of 5-year survival in 
systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann 
Rheum Dis 2011; 70: 1788–1792 
31. Sticherling M. Systemic sclerosis - focus on dermatological aspects. Part 2: diagnostics, 
therapy. J Dtsch Dermatol Ges 2012; 10: 783–791. 
32. Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud’s 
phenomenon resistant to vasodilatory therapy. Circulation 2005; 112: 2980–2985. 
33. Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterase type 5 inhibition is a 
novel therapeutic option in Raynaud disease. Arch Intern Med 2006; 166: 231–233. 
34. Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. 
Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: 
systematic review and meta-analysis of randomised trials. Ann Rheum Dis 2013; 72: 1696–
1699. 
35. Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud’s phenomenon with the 
selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001; 40: 1038–1043. 
36. Hughes M, Ong VH, Anderson ME, et al. Consensus best practice pathway of the UK 
Scleroderma Study Group: digital vasculopathy in systemic sclerosis. Rheumatology 2015; 
54: 2015–2024. 
81 
37. Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with 
Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, 
double-blind study. Ann Intern Med 1994; 120: 199–206. 
38. Pope J, Fenlon D, Thompson A, et al. Iloprost and cisaprost for Raynaud’s phenomenon in 
progressive systemic sclerosis. Cochrane Database Syst Rev 2000; (2): CD000953. 
39. Bali G, Aberer E. Iloprost therapy in systemic sclerosis. Hautarzt 2003; 54: 845–851. 
40. Riemekasten G, Hoffmann U, Sunderkötter C, Weiss N, Kuhn A; angiologisch-
dermatologisch-rheumatologische DU-Expertenboard. Management of digital ulcers in 
patients with systemic sclerosis. Dtsch Med Wochenschr 2012; 137: 34–40. 
41. Herrick AL. Contemporary management of Raynaud’s phenomenon and digital ischaemic 
complications. Curr Opin Rheumatol 2011; 23: 555–561 
42. Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital 
ulcers in systemic sclerosis. Arthritis Care Res 2013; 65: 1460–1471. 
43. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: 
prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis 
Rheum 2004; 50: 3985–3993. 
44. Seibold JR, Denton CP, Furst DE, et al. Bosentan prevents occurrence but does not speed 
healing of digital ulcers in patients with systemic sclerosis (SSc). Arthritis Rheum 2005; 
52(Suppl 9): 552. 
45. Matucci-Cerinic M, Denton CP, Furst DE, et al Bosentan treatment of digital ulcers related 
to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-
controlled trial. Ann Rheum Dis 2011; 70: 32–38. 
46. Morita A, Sakakibara S, Sakakibara N, Yamauchi R, Tsuji T. Successful treatment of 
systemic sclerosis with topical PUVA. J Rheumatol 1995; 22: 2361–2365. 
47. Kreuter A, Breuckmann F, Uhle A, et al. Low-dose UVA1 phototherapy in systemic 
sclerosis: effects on acrosclerosis. J Am Acad Dermatol 2004; 50: 740–747. 
48. Connolly KL, Griffith JL, McEvoy M, Lim HW. Ultraviolet A1 phototherapy beyond 
morphea: experience in 83 patients. Photodermatol Photoimmunol Photomed 2015; 31: 
289–295. 
49. Rook AH, Freundlich B, Jegasothy BV, et al. Treatment of systemic sclerosis with 
extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol 1992; 
128: 337–346. 
50. Knobler RM, French LE, Kim Y, et al. A randomized, double-blind,placebo-controlled 
trial of photopheresis in systemic sclerosis. J Am Acad Dermatol 2006; 54: 793–799. 
82 
51. Knobler R, Berlin G, Calzavara-Pinton P, et al. Guidelines on the use of extracorporeal 
photopheresis. J Eur Acad Dermatol Venereol 2014; 28(Suppl 1): 1–37. 
52. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. 
Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week 
randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 
1996; 35: 364–372. 
53. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate 
versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351–1358. 
54. Walker KM, Pope J, participating members of the Scleroderma Clinical Trials Consortium 
(SCTC); Canadian Scleroderma Research Group (CSRG). Treatment of systemic sclerosis 
complications: what to use when first-line treatment fails-a consensus of systemic sclerosis 
experts. Semin Arthritis Rheum 2012; 42: 42–55. 
55. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in 
scleroderma lung disease. N Engl J Med 2006; 354: 2655–2666. 
56. Balin SJ, Wetter DA, Andersen LK, Davis MD. Calcinosis cutis occurring in association 
with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 
1996–2009. Arch Dermatol 2012; 148: 455–462. 
57. Wu JJ, Metz BJ. Calcinosis cutis of juvenile dermatomyositis treated with incision and 
drainage. Dermatol Surg 2008; 34: 575–577. 
58. Saddic N, Miller JJ, Miller OF 3rd, Clarke JT. Surgical debridement of painful fingertip 
calcinosis cutis in CREST syndrome. Arch Dermatol 2009; 145: 212–213. 
59. Murray AK, Moore TL, Richards H, Ennis H, Griffiths CE, Herrick AL. Pilot study of 
intense pulsed light for the treatment of systemic sclerosis-related telangiectases. Br J 
Dermatol 2012; 167: 563–569. 
60. Halachmi S, Gabari O, Cohen S, Koren R, Amitai DB, Lapidoth M. Telangiectasis in 
CREST syndrome and systemic sclerosis: correlation of clinical and pathological features 
with response to pulsed dye laser treatment. Lasers Med Sci 2014; 29: 137–140. 
61. Dinsdale G, Murray A, Moore T, et al. A comparison of intense pulsed light and laser 
treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized 
trial. Rheumatology 2014; 53: 1422–1430. 
62. Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in 
idiopathic pulmonary fibrosis: an analysis of data from three randomized controlled trials. 
Lancet Respir Med 2013; 1: 369–376. 
83 
63. Van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation 
vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a 
randomized clinical trial. JAMA 2014; 311: 2490–2498. 
64. Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell 
transplantation compared with pulse cyclophosphamide once per month for systemic 
sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498–506. 
65. Ntoumazios SK, Voulgari PV, Potsis K, Koutis E, Tsifetaki N, Assimakopoulos DA. 
Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. 
Semin Arthritis Rheum 2006; 36: 173–181. 
66. Nikou GC, Toumpanakis C, Katsiari C, Charalambopoulos D, Sfikakis PP. Treatment of 
small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven 
patients. J Clin Rheumatol 2007; 13: 119–123. 
67. Frech TM, Khann D, Maranian P, et al. Probiotics for the treatment of systemic sclerosis-
assocated gastrointestinal bloating/distention. Clin Exp Rheumatol 2011; 29(2 Suppl 65): 
S22–25. 
68. Knafo R, Haythornthwaite JA, Heinberg L, Wigley FM, Thombs BD. The association of 
body image dissatisfaction and pain with reduced sexual function in women with systemic 
sclerosis. Rheumatology 2011; 50: 1125–1130. 
69. Foocharoen C, Tyndall A, Hachulla E, et al. Erectile dysfunction is frequent in systemic 
sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and 
Research group. Arthritis Res Ther 2012; 14: R37 
 
  
84 
IV  Nephrogenic systemic fibrosis 
 
Definition 
Nephrogenic fibrosing dermopathy, a dermatologic form of the generic term nephrogenic 
systemic fibrosis (NSF), is a relatively new disease entity. It was first reported in 2000 and is 
believed to be seen almost only in patients with moderate-to-severe kidney failure, particularily 
patients on dialysis.1 It was linked to the usage of gadolinium-based contrast agents (GBCAs) 
in magnetic resonance imaging (MRI), which were adopted in the late 1990s for use in patients 
with impaired renal function, as it was widely accepted that these agents were not nephrotoxic.2 
 
Epidemiology 
Depending on the type of gadolinium used for the imaging process, the incidence rate of NSF 
may vary and, for gadodiamide, it has been estimated to be between 3% and 7% in patients with 
renal insufficiency.3 Accumulating reports on clinically relevant fibrosing processes led to the 
release in 2006 of an alert by the US Food and Drug Administration (FDA) regarding the use 
of GBCA in patients with renal insufficiency.4 Based on multicenter retrospective reviews5,6 
and a European Medicines Agency (EMA) report,7, important risk factors for NSF have been 
identified (Table 1). Other incriminated factors such as erythropoietin, which gained 
widespread use at the time NSF emerged, or hepatic insufficiency, could not be confirmed. The 
adapted, selective use of GBCA thereafter led to a reduction in the incidence of NSF to zero – 
or almost zero.10 However, as there is no mandatory reporting system for NSF, and given that 
the only NSF registry (with over 380 reported cases) was last updated back in June 2013,11 the 
decline in the number of publications reporting new cases has to be taken as a surrogate marker 
for the assumed reduction in incidence.  
 
<TABLE 1> 
 
Pathogenesis 
It has been proposed that excess GBCA in patients with renal insufficiency undergoing MRI 
may be deposited in the tissue upon transmetallation. GBCAs include lanthanides, which were 
reported to induce profibrogenic processes decades ago.12,13 More recently, chelated 
gadodiamide and gadopentetate forms of GBCA specifically have been shown to increase the 
release of profibrotic cytokines and growth factors in macrophages/monocytes in vitro within 
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minutes upon receptor-mediated cellular uptake.14 The exact mechanism of increased collagen 
bundle deposition in skin and other organs has not yet been fully understood.  
 
On routine light microscopy, depending on the disease severity, a deep biopsy may show 
fibrocyte proliferation ranging from subtle proliferation of dermal fibrocytes in early lesions to 
florid proliferation. Thick collagen bundles with surrounding clefts are a prominent finding, 
with a variable increase in dermal mucin and elastin. Immunohistochemical staining shows 
CD34+ dermal dendritic cells. Gadolinium may be visualized with special testing but is not 
diagnostic.15 
 
Clinical manifestation  
NSF is a rare differential diagnosis of other sclerosing skin processes that may occur in patients 
with impaired renal function, such as scleromyxedema, lipodermatosclerosis, eosinophilic 
fasciitis, or localized and systemic sclerosis. Initial symptoms include hyperpigmented skin 
areas and papules, which may coalesce to patches and plaques with a peau d’orange appearance. 
NSF commonly forms symmetrical lesions, which are predominantly located on the lower legs, 
and develops within the first 2–8 weeks after exposure to GBCA.10 Pain and pruritus are 
frequent symptoms, but unlike in eosinophilic fasciitis, fever, arthritis and malaise are 
uncommon.16 Unlike systemic sclerosis, Raynaud's phenomenon is typically absent. Systemic 
involvement has been described (scleral plaques, muscle fibrosis and induration, flexion 
contractures, fibrosis of vessel walls of internal organs such as lung and kidney, calcification 
of the soft tissue). The sclerosing process may proceed within days or weeks, but delayed onset 
of NSF has been described up to 10 years after gadolinium uptake.17 NSF has been documented 
in all age groups, including in children.18 
 
Diagnostic procedures  
There is no specific test available for the diagnosis of NSF. Abnormal creatinine and increased 
blood urea nitrogen are to be considered in the context of the pre-existing renal insufficiency. 
Antinuclear antibodies and rheumatoid factors are typically negative, and there is no association 
with paraproteinemia. Some patients show eosinophilia in the peripheral blood. Girardi et al., 
proposed a scoring system that has been tested on the reported cases in the NSF registry.19 
(Table 2, Fig. 1). The variety of clinical findings in NSF are classified into major (patterned 
plaques of the skin, joint contractures, cobblestone appearance of the skin, peau d’orange) and 
minor (linear banding of the skin, superficial plaque/patch, dermal papules, scleral plaques in 
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patients aged <45 years) clinical criteria, and a clinicopathologic scoring system has been 
proposed in order to allow the diagnostic of NSF.19 As the incidence of NSF appears to 
diminish, evaluation of this scoring system will be a difficult task. Nevertheless, the use of this 
score will aid the standardization of diagnostic procedures for NSF, and may be helpful to 
differentiate between borderline cases of NSF and other sclerosing skin disorders. 
 
<TABLE 2> 
<Fig. 1> 
 
Treatment 
Established NSF lesions do not respond to systemic or local glucocorticoid treatment or to other 
immunosuppressive drugs. Other approaches such as extracorporeal photopheresis, UVA1 
phototherapy, plasmapheresis, or imatinib mesylate have been used with inconsistent clinical 
improvement.20–27 Based on the published data, no specific therapeutic recommendation can be 
made. Reconstitution of renal function is considered the best therapeutic approach.28 Prevention 
consists of avoidance of gadolinium-containing contrast agents in patients with an estimated 
glomerular filtration rate of <30 mL/min. If clinical conditions require the use of gadolinium, 
then, in order to reduce the risk of NSF development, and based on the recommendations of the 
FDA and EMA, low-risk gadolinium media should be the contrast agents of choice. Doses of 
GBCA should be reduced to the minimum effective dosage for imaging.7,8 Based on the 
dialysability of GBCA, it is recommended that at least one full 4-hour dialysis session is 
performed after GBCA-based MRI in patients with renal insufficiency; this should remove 97% 
of the GBCA that was present peior to dialysis. Three full sessions of dialysis increase the 
GBCA clearance up to 99.7%.29 
 
Conclusions 
NSF is an iatrogenic condition observed in patients with end-stage renal failure and is associated 
with gadolinium exposure. No treatments with proven efficacy based on randomised controlled 
trials are available. Avoidance of high-risk GBCA is the key prophylactic measure. 
Prophylactic measures have led to a significant drop in incidence of NSF.30  
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Table 1 Risk factors for nephrogenic systemic fibrosis5–9 
 
Use of GBCA-based MRI in patients with acute or chronic renal insufficiency (GFR <30 mL/min/1.73m2) 
Use of higher-than-standard dose of GBCA for MRI 
Current inflammatory or thrombotic episodes in patient 
Risk stratification based on GBCA type 
High-risk GBCA 
• Linear non-ionic chelates (gadoversetamide [OptiMARK®], gadiodiamide [Omniscan®]) 
• Linear ionic chelates (gadopentetic acid [Magnevist®, Gado-MRT-ratiopharm®, Magnegita®, Marktiv®]) 
Medium-risk GBCA 
• Linear ionic chelates including gadofosveset trisodium (Vasovist®), gadoxetic acid disodium (Primovist®), and 
gadobenate dimeglumine (MultiHance®)  
Low-risk GBCA 
• Macrocyclic chelates (gadoteric acid [Dotarem®], gadoteridol [ProHance®], gadobutrol [Gadovist®]) 
 
GBCA, gadolinium-based contrast agents; GFR, glomerular filtration rate; MRI, magnetic resonance imaging. 
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Table 2 Girardi score for diagnosis of NSF19 
 
Clinical findings  
Major criteria 
• Patterned plaques 
• Joint contractures 
• “Cobblestoning” 
• Marked induration/Peau d’orange 
Minor criteria 
• Puckering/linear banding 
• Superficial plaque/patch 
• Dermal papules 
• Scleral plaques (age <45 years) 
 
Histologic findings 
• Increased dermal cellularity (score +1) 
• CD34+ cells with tram-tracking (score +1) 
• Thick and thin collagen bundles (score +1) 
• Preserved elastic fibers (score -1 if absent) 
• Septal involvement (score +1) 
• Osseous metaplasia (score +3) 
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Figure 1 Girardi score table based on clinical and histologic scoring (see Table 2).19  
 
Pathology score Clinical score 
0 1 2 3 4 
0 Alternative 
Diagnose 
 
 
1 Not NSF  Inconsistent 
with NSF 
2 
 
Suggestive for 
NSF 
Consistent with NSF 
3 
 
Consistent with 
NSF 
NSF 
4 Inconsistent 
with NSF 
NSF, nephrogenic systemic fibrosis. 
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V  Systemic sclerosis overlap syndromes  
Introduction 
Systemic sclerosis (SSc) overlap syndrome is a term used to describe a very heterogeneous 
group of patients with features of different connective tissue diseases, combined with clinical 
signs of SSc.1–3. To date, no firm classification criteria for SSc overlap syndromes have been 
established, but they are generally considered when musculoskeletal involvement or features of 
other rheumatic diseases are significantly greater than usually found in general SSc patients.4,5 
Other autoimmune rheumatic disorders are classified depending on internationally accepted 
classification systems.6–10 Most SSc overlap syndromes appear to encompass a subtype of SSc 
similar to limited cutaneous SSc (lcSSc), but with more frequent involvement of the 
musculoskeletal system than in lcSSc or diffuse cutaneous (dcSSc), and an apparently earlier 
onset of lung fibrosis or heart involvement.5. 
 
Epidemiology 
SSc overlap syndromes represent the third major subgroup of SSc, and epidemiologic studies 
report divergent frequencies (incidence and prevalence rates are not reported yet) of overlap 
subgroups, ranging between 9% and 38% (Table 1).1,2,4,5  
 
The most common SSc overlap syndromes are SSc and myositis (polymyositis or 
dermatomyositis), SSc and rheumatoid arthritis, SSc and Sjögren’s, and SSc and systemic lupus 
erythematosus (SLE) overlap syndromes.4 Pakozdi et al. reported recently that 20% of SSc 
patients attending the Centre for Rheumatology at the Royal Free Hospital (London, UK) had 
features overlapping with other rheumatologic diseases. Of these 43% overlapped with 
polymyositis/dermatomyositis, 8% with SLE, 17% with Sjögren’s syndrome, and 32% with 
rheumatoid arthritis.4 The German Network for Systemic Scleroderma (DNSS) reported that 
10% of the registered patients suffered from SSc overlap syndromes.5  
 
A recent meta-analysis has revealed that the mean age at diagnosis of patients with SSc overlap 
syndromes was 47.6 years (SD 2.6), and that it was found more often in European patients than 
in patients from North America.11 
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Balbir-Gurman reported that the overall mortality in their SSc overlap cohort did not differ from 
other SSc patients.1 Depending on different geographical regions/centers, a wide range of 
frequencies of SSc overlap syndromes have been reported (Table 1). 
 
<TABLE 1> 
 
Pathogenesis 
To date, the pathogenesis of SSc overlap syndromes remains unclear. The question of why some 
patients develop only one connective tissue disease and other patients have a combination of 
clinical features of different rheumatic diseases has not yet been answered. A common or 
overlapping genetic susceptibility possibly plays an important role. Genetic studies have shown 
the existence of some susceptibility genes, which predispose to multiple autoimmune 
diseases.11 Koumakis et al. reported that a regulatory gene located in the TNFAIP3 region is 
associated with a higher risk of developing SSc polyautoimmunity.11,16 
 
Clinical manifestations 
Clinical features of SSc overlap syndrome are very heterogeneous. Patients usually present with 
skin sclerosis typical of lcSSc, although organ manifestations clearly separate these patients as 
distinct subset.5 A German study showed that patients suffering from SSc overlap syndromes 
developed an involvement of the musculoskeletal system significantly earlier and more often 
than patients with dcSSc and lcSSc. In addition, they interestingly developed lung fibrosis and 
heart involvement significantly earlier and more often than lcSSc patients, but still less 
frequently and later than dcSSc patients.5 
 
Therefore, the identification of these patients is essential for clarifying prognosis and 
facilitating therapeutic options. The clinical signs include both cutaneous and extracutaneous 
features, depending on the overlapping connective tissue disease (CTD), and often overlap 
between the different overlap forms, especially regarding vasculopathy, gastrointestinal and 
cardiopulmonary involvement.  
 
For more details on thje following conditions, please refer to Section III (Systemic sclerosis). 
 
Raynaud’s phenomenon 
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Raynaud’s phenomenon is also a very common feature in patients with SSc overlap syndromes.3 
Some SSc overlap patients also develop digital ulcerations but significantly less often compared 
with lcSSc and dcSSc patients.5 
 
Skin sclerosis 
The skin sclerosis in patients with SSc overlap syndromes can be generalized, similar to the 
diffuse form of SSc, but more frequently it is only located below the elbow and knee joints, 
which is similar to the limited form of SSc.4,5  
 
Calcinosis cutis 
Calcinosis cutis can be also observed in patients with SSc overlap syndromes. It is associated 
with longer disease duration, positive anti-centromere and anti-PM/Scl antibodies, and occurs 
usually over pressure points (acral or next to joints).17 
 
Gastrointestinal involvement 
As in SSc the involvement of the gastrointestinal tract is probably the most common internal 
organ system involved (approx. 50–60%).5,14 
 
Lung fibrosis and myocardial involvement 
Lung fibrosis and myocardial involvement are significantly less frequent than in patients with 
diffuse SSc, but significantly more frequent than in limited forms of SSc.5  
 
Pulmonary arterial hypertension 
Pulmonary arterial hypertention (PAH) occurs less frequently in patients with SSc overlap 
syndromes than in patients with dcSSc, but similarly to those with the limited form of SSc.5 
 
Clinical characteristics of systemic sclerosis overlap syndromes 
Systemic sclerosis and myositis 
Myositis is the most frequent systemic involvement in patients with SSc overlap syndromes. In 
some SSc patients, muscle weakness, pain, and atrophy result from disuse secondary to joint 
contractures, dermatogenous contractures, or chronic disease. However, significantly more 
patients with SSc overlap syndromes present with myositis, characterized by proximal muscle 
weakness with no loss of reflexes or sensitivity, myalgia, increased creatine kinase serum levels, 
and later atrophy of muscles. Patients suffering from SSc-myositis overlap syndrome may 
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develop myositis simultaneously, before, or in already established SSc.1 Some patients may 
show cutaneous symptoms of dermatomyositis. The limited extent of skin thickening is still the 
most frequent form in patients with SSc overlap syndromes.1,4,5 
 
Recent studies have shown that an increased proportion of patients also develop lung 
fibrosis,5,18 which is in line with a high percentage (up to 30%) of interstitial lung disease (ILD) 
in patients with dermatomyositis. Patients with SSc-myositis overlap syndromes have a higher 
risk of developing a diffuse interstitial myocardial fibrosis, which may lead to diastolic 
dysfunctions as well as restricted contractibility of the myocardium. These patients typically 
present symptoms, such as cardiac arrhythmia, paroxysmal tachycardia, incomplete or complete 
right-heart blocks, finally leading to heart insufficiency. The frequency of lung and 
gastrointestinal involvement varies among studies, ranging between 32.0% and 78.1%.2  
 
It is well established that patients suffering from the SSc-myositis overlap syndrome (except 
those with antibody to PM/Scl) have a worse prognosis due to an increased risk of myocardial 
involvement compared with patients with only SSc.18 SSc-myositis overlap syndromes may be 
associated with specific autoantibodies, including PM/Scl, anti-Ku, anti-U2RNP, and anti-
U5snRNP (Table 2).1,19 Patients, carrying the antibody to PM/Scl are usually younger, have 
limited skin involvement, and suffer from arthritis and a benign course of ILD,1 which is also 
the reason for their better survival.15 Positive antibodies against Ku are more characteristic for 
patients suffering from muscle involvement as well as severe ILD (Table 1).23  
 
<TABLE 2> 
 
Systemic sclerosis and rheumatoid arthritis 
Joint involvement is reported to be the second most frequent manifestation in patients with 
musculoskeletal involvement and overlap syndromes.4 These patients may present with typical 
clinical symptoms (usually limited skin involvement, morning stiffness, arthritis), together with 
high titers of anti-cyclic citrullinated peptides (CCP/ACPA) and/or higher rheumatoid factors 
(SSc-RA overlap syndrome). However, it is often very difficult to distinguish between SSc 
patients with mild, sero-negative arthralgia and the significant arthritis associated with SSc-RA 
overlap syndrome.  
 
Systemic sclerosis and systemic lupus erythematosus 
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This subtype is a very rare condition.24 Patients often have a fatal course of the disease due to 
a higher risk of developing polyserositis, pancreatitis, avascular bone necrosis, PAH, lung 
involvement, lupus gromelunephritis, skin rashes, and leukencephalopathy.1 It is also difficult 
to distinguish whether the patient suffers from a lupus-nephritis or a scleroderma renal crisis. 
Depending on the reason for renal failure, patients need a different therapeutic strategy to 
improve renal function. Skin lesions can be a major esthetic disturbing factor, because of the 
predilection for the face. These patients usually have a combination of SSc-associated 
antibodies and double-stranded DNA antibodies. 
 
Systemic sclerosis and Sjögren’s syndrome 
This SSc overlap syndrome was first described in 1965 by Bloch et al.25 Xerostomia and 
xerophthalmia are very common in patients suffering from SSc (68–83%), but only 14–20% of 
SSc patients really fulfill the criteria of Sjögren’s syndrome,26 so that the diagnosis of SSc/SS 
overlap syndromes is always a challenge.27 It is defined by a lymphocytic infiltration of the 
salivary glands.  Patients with SSc-SS overlap syndrome show a limited form of skin 
involvement (83.6% vs 16.4%) and a very low frequency of lung involvement.1 Antibodies 
against Ro are very likely in SSc-SS overlap syndromes, often together with anti-centromere 
antibodies (ACA).4  
 
Mixed connective tissue disease 
Mixed connective tissue disease (MCTD) was first described by Sharp et al. in 1972.28 These 
patients present clinical symptoms typically found in patients with myositis, SLE, inflammatory 
arthritis (RA) and SSc. Typical for this condition are puffy fingers (50%), polyarthritis (65%), 
Raynaud’s phenomenon (53%), sclerodactyly (35%), muscle involvement, and esophageal 
involvement.20,29 and the occurrence of high antinuclear antibodies titers with high levels of 
U1snRNP antibodies, which helps to differentiate MCTD from other connective tissue diseases. 
Arthralgia occurs in approximately 60% of patients, and muscle disease is present in 80–90% 
of cases with proximal muscle involvement and elevation of serum creatine kinase levels.29 
Cardiovascular involvement (lung fibrosis and especially PAH) is less frequent, but is a major 
contributor to a poor outcome/prognosis.20 
 
SSc may also occur together with other organ-specific autoimmune diseases, such as 
autoimmune hepatitis/primary biliary cirrhosis, autoimmune thyroiditis, sarcoidosis, and 
antiphospholipid syndrome (Table 3).  
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<TABLE 3> 
 
Diagnostic procedures 
Muscle involvement (myositis/myopathy) 
Typical clinical symptoms include a symmetrical proximal muscle weakness, muscle pain, 
and/or muscle atrophy with intact reflexes and sensitivity. Serologic tests usually show an 
elevation of serum creatine phosphokinase (≥4-fold) and acute phase parameters in blood (e.g. 
C-reactive protein and erythrocyte sedimentation rate. An electromyography, magnetic 
resonance imaging (MRI), and muscle biopsy will help to identify affected muscles.6,7,14,30  
 
Sjögren’s symptoms 
Due to a reduced glandular function, patients with SSc-Sjögren’s overlap syndrome suffer from 
dry mouth (xerostomia) and dry eyes (xerophthalmia). In addition, these patients also typically 
show anti-Ro and anti-La antibodies, often together with anti-centromere antibodies. Further 
diagnostics include functional tests for ocular and oral sicca symptoms, together with a 
glandular biopsy.31 
 
Joint involvement 
A rheumatologic examination is essential to identify rheumatoid arthritis. Joint involvement 
can be due to dermatogenous contractures or inflammation. It is recommended to examine the 
rheumatoid factor and anti-CCP antibodies in the serum of affected patients. X-ray, ultrasound 
of affected joints, as well as MRI scans can be helpful tools to identify inflammation areas and 
damage of the joints.14 
 
Kidney involvement 
Creatinine clearance, urine analysis to control proteinuria and hematuria, as well as regular 
blood pressure tests are necessary for the early identification of renal involvement.14,32 In 
patients with SSc-SLE overlap syndromes it may be necessary to perform a kidney biopsy to 
distinguish between renal failures due to lupus nephritis33 (see also the ACR/EULAR guidelines 
on SLE) or scleroderma renal crisis32 (see also Section III – Systemic sclerosis).32 
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For more details on diagnostic procedures and SSc-associated organ manifestations/ 
complications see Section III (Systemic sclerosis). 
 
<FIG. 1> 
 
Treatment 
There have been major advances in treating many of the organ-specific complications of SSc 
and overlapping diseases. See also Section III (Systemic sclerosis). 
 
Systemic glucocorticoids 
Systemic glucocorticoids can be used for musculoskeletal involvement together with other 
immunosuppressive agents. The use of high-dose glucocorticoids should be used with caution 
due to the increased risk of renal crisis in SSc patients with diffuse extent of skin involvement.2 
 
Methotrexate 
Methotrexate is a well-known immunosuppressive agent that has been used in adults and 
children, with well-documented side-effects. Methotrexate is still a first-line therapy in many 
autoimmune diseases. It is the treatment of choice in patients with SSc-myositis and SSc-RA 
overlap syndromes.34,35  
 
Mycophenolat mofetil 
MMF is a well-tolerated immunosuppressive agent, which is recommended as long-term 
therapy in scleroderma and has successfully been applied in several overlap syndromes.  
 
Azathioprine 
This immunosuppressive agent is usually well tolerated and has been used successfully in 
patients with MCTD as well as patients with SSc-SLE overlap. However, compared with MMF, 
side-effects seem to be more pronounced and the response to the therapy more limited. 
 
Cyclophosphamide 
Cyclophosphamide is often used for lung involvement in patients with SSc,36 and also SSc-
myositis overlap or SSc-SLE overlap syndromes, in case of lupus nephritis. Cyclophosphamide 
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should be used for musculoskeletal involvement as a second-line immunosuppressive therapy 
after other treatments (methotrexate, MMF) have failed or cannot be used due to defined side-
effects. As in other autoimmune diseases, it can be used as intravenous pulse or oral treatment. 
 
Bioimmunomodulatry agents 
Only limited information is available for the use of intravenous immunoglobulin (IVIg), 
rituximab, and anti-tumor necrosis factor (TNF) in the treatment of overlap syndromes.  
 
Therapeutic approaches 
Systemic sclerosis and myositis 
In this group of patients, treatment is mainly directed against muscle inflammation, alveolitis, 
and skin sclerosis (Fig. 2).  
 
Glucocorticoid therapy (not in patients with a higher risk for renal crisis (see Section III – 
Systemic sclerosis), methotrexate (not in case of alveolitis), azathioprine, IVIg, 
cyclophosphamide, and rituximab (in patients with uncontrolled myositis) may be helpful 
agents.  
 
Agents of choice in mild cases are methotrexate together with low-dose glucocorticoids. In 
severe cases, IVIg can be added. In patients with a refractory course of the disease, 
cyclophosphamide (also known to improve skin and lung involvement), MMF (also known to 
improve skin thickening), or rituximab (also known to improve skin and lung involvement) can 
be tried to improve clinical symptoms.1,37–39  
 
Systemic sclerosis and rheumatoid arthritis 
These patients are usually treated with hydroxychloroquine, possibly together with 
methotrexate and low-dose glucocorticoids. If this therapeutic strategy is not effective, 
tocilizumab, rituximab as well as anti-TNF agents should be considered. All these treatments 
have to be used with caution, in the context of serious infections, tuberculosis, and fibrosis.  
 
For further details see Section III (Systemic sclerosis) and ACR/EULAR guidelines on 
rheumatoid arthritis.40 
 
Systemic sclerosis and systemic lupus erythematosus 
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Treatment in patients with cutaneous lesions due to SLE should start with topical glucocorticoid 
therapy, together with UV skin protection. The topical treatment can be combined with 
hydroxychloroquine together with low-dose glucocorticoids. In severe cases, 
cyclophosphamide or MMF can be initiated. The treatment of renal involvement differs 
between a lupus- and a scleroderma-associated renal failure (cyclophosphamide vs vasoactive 
treatment with ace inhibitors and iloprost).  
 
For further details see Section III (Systemic sclerosis) and EULAR/ACR guidelines on 
rheumatoid arthritis.40 
 
Mixed connective tissue disease 
Patients with MCTD usually respond well to systemic glucocorticoid and immunosuppressive 
therapy with several classical agents. But some long-term studies have shown that a group of 
patients with MCTD develop more severe organ manifestations and need a more aggressive 
therapeutic strategy. Inflammatory features (elevated temperature, serositis, pleuritis, myositis, 
and arthritis) respond well to glucocorticoid treatment, while symptoms, such as sclerotic skin 
changes and cardiopulmonary involvement need immunosuppressive/cytotoxic drugs.29,41 The 
most frequently used drugs are hydroxychloroquine, methotrexate, and cyclophosphamide.29  
 
Systemic sclerosis and Sjögren’s overlap syndrome 
Clinical features such as the xerostomia can usually be improved by using various antiseptic 
mouth rinse and saliva substitutes. Xerophthalmia can be improved by using artificial tear 
drops.42 This topical treatment should be combined with hydroxychloroquine and low-dose 
glucocorticoids. In severe cases, cyclophosphamide, azathioprine, or rituximab have shown to 
be effective in open-label studies.43 
 
For further details see Section III (Systemic sclerosis) and guidelines for Sjögren’s syndrome.44 
<Fig. 2>  
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Table 1 Frequencies of different systemic sclerosis overlap syndromes (with references)2 
SSc overlap syndrome Frequency of syndrome* Total 
SSc 11812, 71913, 148314, 1651, 17004, 242515 66102 
SSc overlap syndromes 32.2%12, 38%13, 10.9%14, 24.2%1, 20%4, 9.2%15 16.2%2 
  SSc–polymyositis or SSc–dermatomyositis  5.3%12, 47.5%1, 42.8%4, 60.1%15 44.6%2 
  SSc–Sjögren’s syndrome 26.3%12, 18%13, 42.5%1, 16.8%4 18.5%2 
  SSc–rheumatoid arthritis 8%12, 21.1%13, 15.4%1, 32%4, 6.2%15 19.3%2 
SSc, systemic sclerosis 
*Frequencies of syndromes are shown as a percentage of patients with SSc. 
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Table 2 Autoantibodies associated with systemic sclerosis overlap syndromes 
SSc overlap 
syndrome 
Autoantibodies  
MCTD Anti-U1snRNP (specific), found in 75-90% of MCTD patients20,21 
SSc–myositis Anti-PM/Scl (specific)15 
Anti-Ku, -U1RNP, -Scl70, -Jo1, -Ro/SSA, -U3RNP, -RNA-polymerase have also been 
reported2 
Anti-RuvBL1/2 antibody is a new SSc-related autoantibody, associated with muscle 
involvement and diffuse skin thickening22 
SSc–rheumatoid 
arthritis 
High titers of RF (60–72%), ACPA (prevalence of 64%)2 
ACPA more frequent in patients with rheumatoid arthritis features in SSc patients4 
Anti-Scl-70 and anti-ACA antibodies have been reported4 
SSc–Sjogren’s Anti-Ro/SSA and La/SSB have been reported2,4 
Clearly more often associated with ACA2,4  
SSc–SLE  Anti-dsDNA together with anti-Scl70 antibodies have been reported2 
Also, single cases with anti-ACA and -PM/Scl have been reported2 
MCTD, mixed connective tissue disease; SSc, systemic sclerosis; SLE, systemic lupus erythematosus; ACPA, anti-
citrullinated peptide antibodies; ACA, anti-centromere antibodies;. 
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Table 3 Rare cases of systemic sclerosis overlap syndromes1 
SSc overlap syndrome with  Definition 
Antiphospholipid syndrome Incidence varies between 7% and 13%1 
Presence of lupus anticoagulant, anti-cardiolipid or anti-2-glycoprotein-
1 antibodies has been reported in SSc patients,1 and has been associated 
with severe ischemia, PAH, digital loss, thromboembolism 
Sarcoidosis Very rare variant of SSc overlap syndrome 
Elevated temperature, weight loss and hilar adenopathy has been shown 
in SSc sarcoidosis overlap syndromes 
Lung and lymph node biopsy are necessary to diagnose the disease1 
Primary biliary cirrhosis Prevalence ranges between 7% and 15% 
Mostly associated with lcSSc  
Positive ACA reveales a higher risk for lcSSc 
Often clinically silent, but anti-mitochondrial antibodies, elevation of 
cholestatic enzymes, as well as hyperglobulinemia are possible1 
SSc, systemic sclerosis; PAH, pulmonary arterial hypertention; ACA, anti-centromere antibodies; lcSSc, limited 
cutaneous systemic sclerosis. 
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Figure 1 Flow chart for diagnostic procedures in patients with different systemic sclerosis overlap syndromes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SLE, systemic lupus erythematosus; ANA, antinuclear antibodies; MRI, magnetic resonance imaging; ACPA, anti-citrullinated peptide antibodies; ENA, extractable nuclear antigen; ENT, ear, nose, 
throat.  
*Exclude other reason for creatine kinase elevation (drugs, toxins, thyroid dysfunction). 
†Some patients may be rheumatoid factor-negative and/or anti-CCP-negative. 
‡Rule out hepatitis C virus positivity, vasculitis, internal organ manifestation. 
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Figure 2 Flow chart for therapeutic options for different systemic sclerosis overlap syndromes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SSC, systemic sclerosis; SLE, Systemic lupus erythematosus; MTX, methotrexate; IVIg, intravenous immunoglobulin; MMF, mycophenolate mofetil; TNF, tumor necrosis factor.  
*For detailed information, see the ACR/EULAR guidelines. 
 
Systemic sclerosis overlap syndromes 
SSc–myositis SSc–rheumatoid arthritis* SSc–Sjögren’s 
Mild cases: 
MTX + low-dose glucocorticoids 
Severe cases: 
IVIg + MTX + low-dose 
glucocorticoids 
Refractory cases: 
Cyclophosphamide, or 
MMF, or 
Rituximab 
Hydroxychloroquine + MTX + 
low-dose glucocorticoids 
If not effective, consider: 
Tocilizumab, or 
Rituximab, or 
Anti-TNF 
Local therapy + 
hydroxychloroquine + low-
dose glucocorticoids 
If not effective, consider: 
Cyclophosphamide, or 
Azathioprine, or 
Rituximab 
SSc–SLE* 
Local therapy + 
hydroxychloroquine + low-
dose glucocorticoids 
Severe cases: 
Cyclophosphamide, or 
MMF 
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VI  Scleredema 
Introduction 
Scleredema (scleredema adultorum, scleredema of Buschke) is a rare scleromucinous 
connective tissue disease of unknown etiology. The disease is characterized by firm edema of 
the trunk, head, shoulders, and sometimes the thighs, but with hands and feet spared.1 The 
disease was first described back in 1752 by Curzio.2 However, in 1902 Abraham Buschke 
named it “scler-oedem,” when he presented the case of a patient developing skin thickening 
after influenza.3 Buschke also added “adultorum” to the name, suggesting the adult age of 
affected patients. To date, the majority of patients described in the literature have been younger 
than 20 years.1 Therefore, currently, scleredema adultorum is most commonly called 
“scleredema” or “scleredema of Buschke.” 
 
Three types of scleredema can been distinguished.4 They are associated with different preceding 
or underlying conditions. Type 1 usually follows a febrile episode/infection. Type 2 is 
associated with paraproteinemias (including multiple myeloma). Type 3 was named scleredema 
diabeticorum by Krakowski,5 because of its strict association with diabetes mellitus (type 1 and 
2). The pathologic effect of skin hardening in different clinical types of scleredema is the result 
of excessive production of mucin (high molecular weight, heavily glycosylated proteins) and 
collagens by fibroblasts in the reticular dermis.1 
 
Epidemiology 
Scleredema is a very rare condition. Its exact prevalence and incidence are unknown. Thus, 
many cases may be unreported. To our knowledge, there is no racial or ethnic predilection to 
the disease. Scleredema occurs in individuals of all ages, ranging from infancy to adulthood. 
 
Type 1 scleredema, which constitutes 55% of the total number of cases, affects mainly 
children.6 Type 2 scleredema occurs in 25% of cases, whereas type 3 scleredema is observed in 
about 20% of scleredema cases.2 We do not know the proportion of type 1 and 2 diabetes or 
multiple myeloma patients who develop scleredema. More than 50% of patients are aged under 
20 years,7 and they mostly suffer from types 1 or 2 scleredema. In types 1 and 2 scleredema, 
women are affected almost twice as frequently as men. The male to female ratio in type 3 
scleredema is considered to be 10:1.2,6,8 
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Pathogenesis 
The pathogenesis of scleredema remains unknown. Scleredema is a heterogeneous syndrome 
with different concomitant conditions and mechanisms. The excessive production of mucin and 
collagen may be provoked by diverse stimuli, including infections and inflammatory processes, 
drugs, toxins, genetic mutations, immunoglobulins and cytokines, and genetic factors.9,10 The 
pathogenesis of the diabetic type of scleredema is considered to be associated with ischemia, 
hyperinsulinism, or autoimmunity.11 Chronic hyperglycemia is believed to stimulate fibroblast 
proliferation and extracellular matrix components synthesis. It was documented that scleredema 
is also associated with an abnormal expression of extracellular protein genes (type 1 and type 
3 collagens, fibronectin) in the lesions.12 However, non-enzymatic glycosylation progressively 
damages collagen in the connective tissue by altering the mechanism of collagen fiber 
degradation. The lack of lymphocytic infiltrates in the lesions excludes a T-cell-mediated 
etiology.  
 
Clinical manifestations 
The clinical symptoms of scleredema include cutaneous and extracutaneous findings, which are 
present especially in types 2 and 3 scleredema. 
 
Cutaneous manifestations 
In the early stages, scleredema manifests as a woody hardening of the skin of the neck, which 
later spreads to shoulders and the upper part of the trunk. It may affect the face and occasionally 
the thighs, but it rarely affects the hands and feet.11,13,14 The lesions are ill-defined, non-pitting, 
indurated plaques. The affected skin wrinkles or takes on a “peau d’orange” appearance when 
pinched. This induration may occasionally follow a transient erythematous eruption.10,15,16 In 
addition, a diffuse pigmentation of the skin was reported in a patient with type 2 scleredema, as 
melanogenesis seems to be connected with paraproteinemia.17 The skin appendages are usually 
preserved. However, the loss of eccrine glands, causing frequent heat attacks, was observed in 
one patient.18 Cellulitis and delayed wound healing have also been reported.11,19 
 
Extracutaneous manifestations 
Although scleredema classically manifests as skin thickening, the extracutaneous involvement 
of different internal organs is possible, leading to many potentially life-threatening 
complications. Systemic manifestations occur more commonly in types 2 and 3; they are rare 
in type 1 scleredema.20 Limitations in the movement of extremities, difficulties in opening the 
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mouth and eyes, and difficulties in breathing or even restrictive lung disease are the most 
common symptoms. Lesions in various locations may lead to different complications. 
 
Lesions in the eye and periorbital region lead to blepharoptosis, exophthalmos, chemosis, 
conjunctivitis, corneal ulcer, keratitis, restricted eye movement, and ophthalmoplegia.8,10 
Involvement of the tongue, the upper part of the esophagus, ocular muscles, pharynx, parotid 
glands, and vocal cords in the larynx is less common. Involvement of the esophagus can cause 
dysphagia.20–22 These complications are known to have caused aspiration of food and aspiration 
pneumonia.23 
 
Cardiac involvement may result in congestive heart failure, myocarditis, diastolic gallop, 
arrhythmia, and repolarization abnormalities. Hepatomegaly and splenomegaly may be found 
in some patients with scleredema.2 Scleredema may be associated with pleura and lung 
involvement, leading to pulmonary restrictive disease, which can also be the consequence of 
the involvement of the skin and subcutaneous structures of the trunk, or even death.24,25 In some 
patients, these abnormalities may be secondary to skin induration of the trunk.  
 
A very strong relationship between diabetic scleredema and obstructive sleep apnea syndrome 
has been documented.25  
 
Musculoskeletal involvement is associated with dismotility and limitation of motion.2 Some 
authors have reported bone marrow infiltration with calvarial sclerosis or with osteopoikilosis, 
as well as the infiltration of nerve tissue.2,10  
 
Associated disorders 
Scleredema is a heterogeneous disorder that may be associated with various conditions. Type 1 
scleredema usually follows an infection, especially streptococcal respiratory tract infection. 
However, other infective agents that have been reported are: influenza, measles, mumps, 
chicken-pox, cytomegalovirus, diphtheria, encephalitis, mycoplasma pneumonia, and dental 
abscesses.4,6,10,16,26,27 
 
Type 2 scleredema is often associated with paraproteinemia, which is present in 25% of 
scleredema patients, compared with 0.5% prevalence of paraproteins expected in the general 
population.28 Associated conditions include monoclonal gammopathy,6,29–31 multiple 
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myeloma,32–36 and amyloidosis.28 Multiple myeloma is commonly not present at the time of 
scleredema onset. Some patients with scleredema develop multiple myeloma after a few years 
of asymptomatic monoclonal gammopathy. Other associated diseases include primary 
hyperparathyroidism,37,38 rheumatoid arthritis,39,40 ankylosing spondylitis,29 Sjögren’s 
syndrome,40 dermatomyositis,41 Waldenstrom’s macroglobulinemia, anaphylactoid purpura, 
primary biliary cirrhosis,42 IgA deficiency,43 and HIV infection.8,10 Cases of concomitant 
neoplasms have been reported, such as malignant insulinoma,44 gall bladder carcinoma,45 
carcinoid tumor,46 and adrenocorticotropic hormone-producing pituitary tumor.47  
 
Diabetic scleredema (type 3) is associated with type 1 and type 2 diabetes mellitus. However, 
it is associated with insulin resistance and hyperglycemia, and therefore other endocrinopathies 
with insulin resistance (not only diabetes) could be present. In addition, in cases of 
adrenocortical tumors or pituitary adenomas, which are functional, scleredema symptoms refer 
to the metabolic status of hypercortisolism and diabetes/diabetic tendencies.47  
 
Clinical course 
The clinical course of scleredema depends on the type. Type 1 scleredema, which is the classic 
“Buschke” scleredema type, is preceded by a febrile illness (fever over 38°C during 3–4 weeks). 
The onset of scleredema type 1 is abrupt but the prognosis is good and in most cases it resolves 
in a few months to 2 years.6 There have been reports of rare cases of persistent scleredema type 
1 persisting for 10 years. Systemic involvement is uncommon. 
 
Type 2 scleredema is associated with paraproteinemias with no infection in the patient’s history. 
This type is slowly progressive with a non-resolving course.4,6 Systemic involvement is likely 
to occur with serious complications. 
 
Type 3 scleredema (diabetic scleredema) is associated with type 1 or 2 diabetes mellitus. The 
risk factors for scleredema type 3 are: male sex, long course of diabetes, poor metabolic control, 
treatment with insulin, and presence of diabetes-specific complications (especially 
microangiopathy). Other risk factors of diabetic scleredema are hypertension and 
obesity.11,25,48,49 The course of disease is insidious, slowly progressing and non-resolving as in 
type 2, but occasionally it is self-limited. Some cases are complicated by systemic involvement. 
 
Diagnostic procedures 
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Histopathology 
The following histopathologic findings are characteristic for scleredema.  
• The epidermis is usually not involved.  
• The most characteristic finding is increased thickness of the dermis (up to four times thicker 
than normal). It is due to enlarged collagen bundles in deep reticular dermis and the 
presence of wide, clear spaces between them. These fenestrations are filled with mucin. 
Mucin deposits represent non-sulfated acid mucopolysaccharides, mainly hyaluronic acid. 
• The subcutaneous tissue is also affected – fat is replaced by coarse collagen fibers.10  
• Accumulation of mucopolysaccharides is easily found when stained with Alcian blue dye, 
colloidal iron or toluidine blue. However, the absence of glycosaminoglycan deposits is 
possible, and therefore this does not exclude the diagnosis.10,50,51 
• Appendages are usually preserved, unlike in scleroderma. However, some authors have 
reported the loss of eccrine glands.49,50 
 
The diagnosis of scleredema is made clinically, with the definitive diagnosis confirmed by 
histopathology.49,52,53  
 
Diagnostic criteria 
The diagnosis of scleredema is based upon the recognition of the following criteria: 
• typical woody thickening of the skin, which spares acral locations (hands and feet are 
usually not involved);  
• increased thickness of the dermis in the microscopic evaluation with the accumulation of 
mucopolysaccharides; 
• history of a preceding infection, underlying diabetes or paraproteinemia. 
 
In type 2 scleredema no associated diseases (paraproteinemia) may be present at the time of 
diagnosis of scleredema. It is suggested to distinguish type 2a and 2b scleredema. Type 2a 
fulfills all criteria of type 2 scleredema, but with no associated lymphoproliferative disorder. 
Type 2b is scleredema associated with a lymphoproliferative disorder.  
 
Patient history 
The patient is asked about preceding infections. Moreover, the symptoms of malignancies or of 
diabetes/glucose intolerance associated with other endocrinopathies should be carefully 
considered. Identification of possible systemic complications requires questions about 
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difficulties in movement, fatigue (muscle or heart involvement), dysphagia (mainly 
involvement of the upper part of the esophagus), respiratory problems, and neurologic 
symptoms (e.g. paresthesia, pain). 
 
Physical examination 
A full skin examination is performed. The induration of the skin in characteristic locations 
(neck, the upper part of the trunk, shoulders, face) and spared hands and feet suggest the 
diagnosis of scleredema. A modified Rodnan scale (as in scleroderma or scleromyxedema) may 
be used to evaluate the severity of skin involvement and to document its activity. In addition, a 
durometer or an ultrasonography measurement of skin thickness may be performed in order to 
evaluate the severity and to monitor the disease.54  
 
Skin biopsy 
A skin biopsy is required to confirm the diagnosis and to exclude other sclerosis-like disorders. 
A 4 or 5 mm punch biopsy is sufficient. A mucin stain will be positive. Direct 
immunofluorescence is negative and has little, if any, value for differential diagnosis. 
 
Complementary investigations 
At the time of diagnosis, blood tests mainly aim at identifying a lymphoproliferative disorder 
in patients without a recent history of infection and without a history of diabetes. However, as 
the disease is very rare, it is recommended that these tests are performed in all patients. 
Leukocyte count (lymphocytes), serum protein electrophoresis, and serum and urine 
immunofixation must be performed in order to screen for monoclonal gammopathy.49 In cases 
of monoclonal gammopathy, or clinical evidence of enlarged lymph nodes, additional 
investigations should be discussed, including cytofluorometry analysis (looking for B cell 
lymphoproliferation), chest and abdomino-pelvic computed tomography scan ± positron 
emission tomography scan ± lumbar and dorsal magnetic resonance imaging ± 
myelogram/osteomedullar biopsy (Table 1).  
 
<TABLE 1> 
 
During follow-up, in patients with diabetes, fasting glycemia and HBA1c must be monitored. 
In patients with type 2, with or without identified lymphoproliferation, leukocyte count 
(lymphocytes), serum protein electrophoresis, and serum and urine immunofixation must be 
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performed every year, in association with a complete physical examination looking for lymph 
node enlargement and/or hepato-splenomegaly (Table 2).  
 
<TABLE 2> 
 
Other laboratory test may be needed in differential diagnosis to exclude other conditions, 
depending on the clinical presentation. Antinuclear antibodies (ANA), if performed, are 
negative. This test may facilitate differential diagnosis with systemic sclerosis (SSc). 
 
Additional tests 
High-frequency ultrasonography may be performed to monitor the activity and severity of skin 
involvement. In cases of systemic involvement, specific diagnostic examinations are required 
(e.g. pulmonary function tests, ultrasonography of internal organs, including the heart, liver or 
spleen, esophageal manometry, radiography/ultrasonography of bones/joints). 
 
Differential diagnosis 
Scleredema may cause diagnostic difficulties, as the differential diagnosis includes various 
diseases. The characteristic thickness of the dermis and the accumulation of 
mucopolysaccharides distinguish scleredema from other sclerotic disorders.10 Two main 
disorders that require a differential diagnosis are: scleroderma (SSc) and scleromyxedema. 
 
SSc (scleroderma) 
Clinical and histopathologic differences allow for the differentiation. Skin thickening in SSc 
typically begins with involvement of the finger tips, progressing to involve the hands and feet, 
which are spared in scleredema. Other typical clinical findings of SSc, such as Raynaud’s 
phenomenon, abnormal nailfold capillaries, and ANA, are absent in scleredema. 
Histopathology distinguishes the two diseases, and there are no deposits of mucin in SSc. 
 
Scleromyxedema 
Clinically and histopathologically, scleromyxedema is very close to scleredema. However, the 
induration of the skin progresses acrally and typically forms characteristic large folds or firm 
papules, which are absent in scleredema. Systemic complications are common in both diseases. 
The association with monoclonal gammopathy or multiple myeloma is present, similarly to 
scleredema type 2. Mucin deposits are likely to be present. 
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Scleromyositis 
Scleromyositis differs from scleredema by its typical clinical symptoms and common presence 
of ANA, especially PM/Scl. The clinical presentation of edema, which is correlated with heart 
or renal failure, is different from scleredema. However, sometimes there may be some problems 
with differentiation. Edema is usually non-solid, “pitting.” Due to hydrostatic pressure, edema 
is likely to occur in acral locations. The patient has symptoms of heart/renal failure. 
Histopathologically, edema and scleredema are different. Similar clinical presentation and 
differences (as found in edema) may also occur in the course of lymphedema. 
 
Myxedema 
Myxedema is associated with thyroid dysfunction, and is ruled out serologically and clinically, 
by exclusion of thyroid function abnormalities. 
 
Eosinophilic fasciitis 
A typical woody induration in areas corresponding to the anatomic localization of the fascia. 
Typically these are the trunk and extremities, usually sparing the finger tips. Carpal tunnel 
syndrome may coexist. Eosinophilia, if present, may facilitate differential diagnosis. 
Histopathology distinguishes the two disorders; however, the biopsy should be sufficiently deep 
to reach the fascia. Mucin deposits are not present. 
 
Cutaneous amyloidosis 
The term “amyloidosis” is used for a group of disorders with accumulation of various insoluble 
proteins (amyloid). Amyloidosis can be ruled out/confirmed with a microscopic examination. 
Histopathologically, amyloidosis manifests as characteristic amyloid deposits found in the 
affected tissues when stained with Congo red dye. 
 
Lymphedema 
Lymphedema refers to edema, which is usually most strongly expressed acrally, affecting the 
extremities. The removal or damage to lymph nodes is common in the medical history of the 
patient. Lymphedema differs from scleredema histopathologically. The typical findings include 
keratinocyte hyperproliferation, condensed dermal collagen, and mononuclear perivascular 
infiltrate that increases with lymphedema stage. There is no accumulation of 
mucopolysaccharides. 
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Radiotherapy-induced skin thickening 
Radiotherapy-induced skin thickening can be confirmed or excluded by history of preceding 
radiation treatment. Lesions are usually limited to the area exposed to radiotherapy. Mucin 
deposits are not present. Mylona et al. reported scleredema after a radiation treatment.55  
 
Graft-versus-host disease 
Graft-versus-host disease can be confirmed or excluded by history of preceding treatment. 
Examination of skin biopsy for mucin deposits is negative. 
 
Treatment 
The treatment will focus on the underlying condition. Thus, when a potential cause is identified, 
the priority will be the treatment of the cause (Table 3). 
  
In diabetic patients, the control of diabetes is mandatory. If not already prescribed, insulin may 
be necessary. In addition, diabetes should be controlled. Overweight patients should be given 
advise on how to lose weight.  
 
If an infection is identified it may be treated with appropriate anti-infectious agents. However, 
scleredema type 1 does not usually require treatment, as it is self-limited and usually resolves 
in few of months to 2 years.  
 
If a lymphoproliferative disorder is identified, there is a need for discussions with the 
hematologist in order to treat the lymphoproliferative disease itself. Thus, it was reported that 
scleredema may improve after the treatment of a multiple myeloma.32  
 
In the absence of an etiology, if the patient has severe involvement, a treatment can be proposed. 
Unfortunately, the number of patients reported in the literature to benefit from a specific 
treatment is very small, and on that basis it is very difficult to make evidence-based medical 
recommendations. However, based on the available literature, the expert recommendation is to 
use medium-to-high dose ultraviolet light therapy (UVA1 or PUVA) as a first-line treatment.56–
60 If the condition fails to improve, or if PUVA is not available, methotrexate is recommended 
as a second-line treatment. If methotrexate fails, based on a risk–benefit approach, the following 
treatments can be proposed: 
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• cyclosporine A61–63 
• glucocorticoids (systemic or intralesional)64  
• electron-beam radiotherapy6,65–67 
• extracorporeal photopheresis68 
• prostaglandin E169 
• intravenous immunoglobulin70 
• high-dose penicillin71 
• hyaluronidase intralesionally72 
• factor XIII infusion73 
• radiotherapy74 
• cyclophosphamide.36 
 
A significant number of case reports indicate that the most beneficial treatment method is 
photochemotherapy (UVA1, PUVA or narrow-band UVB). The mechanism of the 
improvement remains unclear.49,75 Lack of randomized controlled trials in scleredema creates a 
difficulty in drawing conclusions about the long-term efficacy, optimum dose, and best 
treatment regimens.76 
 
In addition to different systemic treatment modalities, non-pharmacologic treatments can be 
proposed, such as physiotherapy, in order to increase the range of motion of joints and/or 
improve restrictive respiratory insufficiency (Table 3).11  
 
<TABLE 3> 
 
Prognosis and follow-up 
During follow-up, the efficacy of treatments can be assessed using the modified Rodnan skin 
score, Health Assessment Questionnaire, range of motion of involved joints, and the 
Dermatology Life Quality Index (Table 4). 
 
Type 1 scleredema associated with a preceding infection is characterized by a good prognosis 
and even spontaneous resolution. The active phase lasts 2–8 weeks and is followed by a 
resolution in a couple of months to 2 years.77 Scleredema type 1 lesions persisting for 10 years 
are uncommon.78 
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Unlike type 1, type 2, which is associated with blood dyscrasia, should be carefully followed 
up. The prognosis is not good; the lesions are persistent with possible systemic involvement 
leading to life-threatening complications. If only monoclonal gammopathy of unspecified 
significance is present, the risk of multiple myeloma or another related malignancy is about 1% 
per year. Therefore, careful follow-up of patients is required.17 The treatment of underlying 
diseases is crucial; however, this may not be satisfactory in some type 2 scleredema cases.  
 
Diabetic scleredema has a poor prognosis, with a chronic progressive course and systemic 
complications. It also requires follow-up of patients. Monitoring blood glucose and metabolic 
control are beneficial in some cases. Sleep apnea syndrome is common, and specific diagnostic 
tests are necessary to confirm the disorder. As diabetic scleredema is under-recognized, there 
is a need for appropriate education.64 
 
<TABLE 4> 
 
Summary and recommendation 
• Scleredema adultorum is a connective tissue disorder characterized by the thickening of 
the skin. The characteristic location of woody indurated areas is the upper part of the body. 
In contrast to systemic sclerosis, it never affects the acral parts of extremities.  
• There are three types of the disease. Type 1 usually follows a febrile episode/infection. 
Type 2 is associated with paraproteinemias. Type 3 is associated with diabetes. 
• There is no racial or ethnic predilection. Male to female ratio is 1:2 in type 1 and 2 
scleredema, but 10:1 in type 3 scleredema.  
• The pathogenesis of scleredema is unknown. Various conditions and mechanisms are 
related to the excessive production of mucin and collagen, causing the thickening of the 
dermis.  
• The clinical symptoms of scleredema include cutaneous and extracutaneous findings, 
especially in types 2 and 3 scleredema. Decreased mobility of the affected tissues 
commonly causes movement limitations or even respiratory insufficiency.   
• The clinical course of scleredema depends on its type. Three clinical types of scleredema 
are associated with different stimuli which may evoke scleredema of Buschke.  
• Skin biopsy identifies mucin deposits.  
• Type 1 scleredema is preceded by a febrile illness. It is self-limited with a spontaneous 
resolution in a few months to 2 years. 
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• Type 2 scleredema, associated with paraproteinemias (2a with identified paraproteinemia 
at the time of diagnosis, type 2b with paraproteinemia identified during follow-up), is 
slowly progressive with systemic involvement and a poor response to treatment. 
• Type 3 scleredema (diabetic scleredema) is associated with diabetes. The course of disease 
is insidious, slowly progressing, and non-resolving as in type 2, but it is sometimes self-
limited. Systemic complications are likely to occur. 
• The diagnosis of scleredema is made clinically. A histopathologic examination is 
performed to confirm a definitive diagnosis. It is made in cases of woody indurations of 
the skin with increased thickness of the reticular dermis and the accumulation of 
mucopolysaccharides found when stained with Alcian blue. Patient follow-up in types 2 
and 3 scleredema is needed to screen for paraproteinemias and systemic complications or 
to monitor the metabolic status of the patient with diabetic scleredema.  
• Scleredema type 1 does not usually require treatment, as it is self-limited and usually 
resolves in a short period of time. In types 2 and 3 scleredema, the treatment of an 
underlying condition is needed. Better glucose control has been proven to be beneficial in 
some cases. No specific therapy of scleredema is available, although numerous methods 
have been proposed with variable results. The recommended first-line treatment is UV-
based management in monotherapy. If this fails, methotrexate is recommended.   
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Table 1 Scleredema: complementary examinations for etiologic diagnosis 
 
• Leukocyte count (lymphocytes) 
• Serum protein electrophoresis (peak, hypogammaglobulinemia) 
• Immunofixation (serum, urine) 
• CT scan ± PET scanner ± MRI* 
• Myelogram/osteomedullar biopsy* 
 
CT, computed tomography; PET, positron emission tomography; MRI, magnetic resonance imaging. 
*In the presence of enlarged lymph node upon clinical examination or a peak upon protein electrophoresis or 
hypogammaglobulinemia 
 
 
Table 2 Scleredema: complementary exams for follow-up 
 
Type 1 
• None 
 
Type 2 
If no evidence of an etiology, and no resolution, repeat tests annually to identify lymphoproliferative disorder, in 
addition to physical examination  
• Leukocyte count (lymphocytes) 
• Serum protein electrophoresis (peak, hypogammaglobulinemia) 
• Immunofixation (serum, urine) 
 
Type 3 
• Fasting glycemia, HbA1C 
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Table 3 Scleredema: treatment 
 
Treat the identified cause 
• Equilibrate diabetes (type 3) 
• Treat multiple myeloma or other identified lymphoproliferative disorder (type 2) 
 
Non-pharmacologic measures 
• Weight loss, rehabilitation (increase range of motion of involved joints, respiratory rehabilitation) 
 
Specific treatment if severe and no identified cause 
• First line: medium-to-high dose UVA1 or PUVA* 
• Second line: methotrexate (if no UVA1 or PUVA)† 
• Other proposed treatments‡ 
 
*See also section I (Localized scleroderma) 
†With or without glucocorticoids, except in diabetic patients. 
‡Cyclosporine A, glucocorticoids (systemic or intralesional), electron-beam radiotherapy, extracorporeal 
photopheresis, prostaglandin E1, intravenous immunoglobulin, high-dose penicillin, hyaluronidase 
intralesionally, factor XIII infusion, radiotherapy, cyclophosphamide. 
 
 
Table 4 Scleredema: evaluation of treatment efficacy 
 
• Range of motion of involved joints (physical measurements and photos) 
• Modified Rodnan skin score 
• Health Assessment Questionnaire 
• Dermatology Life Quality Index 
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